var title_f1_41_1680="Motility of Shigella";
var content_f1_41_1680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/79774/shgactin_conv.mp4?title=Motility+of+Shigella\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Motility of shigella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Motile intracytoplasmic Shigella bacteria with an actin tail at one pole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcia B Goldberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1680=[""].join("\n");
var outline_f1_41_1680=null;
var title_f1_41_1681="Conjunctival anatomy";
var content_f1_41_1681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Anatomy of the conjunctiva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The conjunctiva is a thin, transparent tissue that covers the outer surface of the eye. It consists of two continuous parts, one on the inner surface of the eyelid (the tarsal conjunctiva), and the other over the sclera (the bulbar conjunctiva). These are outlined in the drawing as a thin pink line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1681=[""].join("\n");
var outline_f1_41_1681=null;
var title_f1_41_1682="Giemsa stain bartonellosis";
var content_f1_41_1682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giemsa stain bartonellosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Maguina, C, Garcia, PJ, Gotuzzo, E, et al. Bartonellosis (Carrion's Disease) in the Modern Era. Clin Infect Dis 2001; 33:772. Copyright &copy; 2001 University of Chicago's Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1682=[""].join("\n");
var outline_f1_41_1682=null;
var title_f1_41_1683="Port placement for foregut surgery";
var content_f1_41_1683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Port placement for foregut surgery*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Veres needle is placed in the upper abdomen to insufflate the peritoneal cavity. A 5 mm port is placed through the Veres tract and the laparoscope is placed. Additional ports are placed under direct vision. The 5 mm port in the subxiphoid region is used for a laparoscopic liver retractor. Right and left subcostal ports (5 mm) are placed and two additional ports are placed midway between these subcostal ports and the umbilicus. One of the midabdominal ports is used to pass the surgical stapler (12 mm) and/or special suturing instruments.",
"    <br>",
"     The surgeon stands on the patient's right side using the dissector and stapler through the right-sided ports (shown in red). The assistant stands on the patient's left side operating the laparoscope with his or her left hand through the 5 mm midabdominal port site, and provides counter-traction for the surgeon through the left subcostal port site (shown in blue). Alternatively, the patient can be placed in a split leg (ie, lithotomy) position, and the surgeon operates from a position between the legs.",
"     <div class=\"footnotes\">",
"      * Port placement and technique may vary amongst laparoscopic surgeons.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1683=[""].join("\n");
var outline_f1_41_1683=null;
var title_f1_41_1684="Stepwise asthma Rx 5 to 11 yrs";
var content_f1_41_1684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Stepwise approach for managing asthma in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 559px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. Theophylline is a less desirable alternative due to the need to monitor serum concentration levels. Step 1 and step 2 medications are based on Evidence A. Step 3 ICS + adjunctive therapy and ICS are based on Evidence B for efficacy of each treatment and extrapolation from comparator trials in older children and adults - comparator trials are not available for this age group; steps 4-6 are based on expert opinion and extrapolation from studies in older children and adults. Immunotherapy for steps 2-4 is based on Evidence B for house-dust mites, animal danders, and pollens; evidence is weak or lacking for molds and cockroaches. Evidence is strongest for immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults. Clinicians who administer immunotherapy should be prepared and equipped to identify and treat anaphylaxis that may occur.",
"    <br/>",
"    <strong>",
"     Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.",
"    </strong>",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; ICS: inhaled corticosteroid; LABA: long-acting inhaled beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist; LTRA: leukotriene receptor antagonist; SABA: inhaled short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1684=[""].join("\n");
var outline_f1_41_1684=null;
var title_f1_41_1685="Sodium iodide I-131: Drug information";
var content_f1_41_1685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium iodide I-131: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/7/15476?source=see_link\">",
"    see \"Sodium iodide I-131: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2521692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hicon&trade;;",
"     </li>",
"     <li>",
"      Iodotope&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2521696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antithyroid Agent;",
"     </li>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2522218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If dose or dose within range exceeds 1000 microcuries, dose will be expressed as",
"     <b>",
"      milli",
"     </b>",
"     curies.  Adhere to radiation safety precautions regarding radioactive iodine treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diagnostic procedures:",
"     </b>",
"     Oral (based on a 70 kg patient):",
"     <b>",
"      Note:",
"     </b>",
"     Consult manufacturer potency tables when applicable. All doses should be individualized; general ranges are listed here:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Thyroid uptake: 5-15 microcuries (or 0.185&ndash;0.555 megabecquerels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Scintiscanning: 50-100 microcuries (or 1.85-3.7 megabecquerels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Localization of extrathyroid metastases: 1000 microcuries (or 37 megabecquerels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Hyperthyroidism:",
"      </i>",
"     </b>",
"     4-10",
"     <b>",
"      milli",
"     </b>",
"     curies (or 148-370 megabecquerels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Dose equation corrected for 24-hour radioactive iodine uptake:",
"     </b>",
"     Activity (",
"     <b>",
"      milli",
"     </b>",
"     curies) = (gland weight in grams x desired dose in microcuries/gram x [1/24 hour uptake on % of dose])/1000",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Graves&rsquo; disease (unlabeled use):",
"     </i>",
"     10-15",
"     <b>",
"      milli",
"     </b>",
"     curies (or 370-555 megabecquerels)",
"     <b>",
"      or",
"     </b>",
"     150 microcuries/g of tissue corrected for 24-hour radioactive iodine uptake (see dose equation) (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Toxic multinodular goiter (unlabeled use):",
"     </i>",
"     150-200 microcuries/g of tissue corrected for 24-hour radioactive iodine uptake (see dose equation); if hyperthyroidism persists, may repeat after 6 months if needed (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Toxic thyroid adenoma (unlabeled use):",
"     </i>",
"     10-20",
"     <b>",
"      milli",
"     </b>",
"     curies (or 370-740 megabecquerels)",
"     <b>",
"      or",
"     </b>",
"     150-200 microcuries/g of tissue corrected for 24-hour radioactive iodine uptake (see dose equation); if hyperthyroidism persists, may repeat after 6 months if needed (Bahn, 2011; Zakavi, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Thyroid cancer:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Iodotope&reg;: Ablation of normal thyroid tissue: Initial: 50",
"     <b>",
"      milli",
"     </b>",
"     curies (or 1850 megabecquerels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Subsequent therapeutic doses: 100-150",
"     <b>",
"      milli",
"     </b>",
"     curies (or 3700-5550 megabecquerels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hicon&trade;: Ablation of normal thyroid tissue: Initial: 30-100",
"     <b>",
"      milli",
"     </b>",
"     curies (or 1100-3700 megabecquerels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Subsequent metastases ablation: 100-200",
"     <b>",
"      milli",
"     </b>",
"     curies (or 3700-7400 megabecquerels)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13317074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If dose or dose within range exceeds 1000 microcuries, dose will be expressed as",
"     <b>",
"      milli",
"     </b>",
"     curies.  Adhere to radiation safety precautions regarding radioactive iodine treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Graves&rsquo; disease (unlabeled use):",
"     </b>",
"     Children &ge;5 years: Oral: Dose is dependent upon gland size; &gt;150 microcuries/g of thyroid tissue is necessary to induce hypothyroidism; if gland is between 50-80 g, higher activities (200-300 microcuries/g of thyroid tissue) may be needed.",
"     <b>",
"      Note:",
"     </b>",
"     Therapy in children between 5-10 years of age is acceptable if the calculated dose is &lt;10",
"     <b>",
"      milli",
"     </b>",
"     curies (Bahn, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2522219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2522262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule [diagnostic]: 0.555 megabecquerels [15 microcuries]; 0.925 megabecquerels [25 microcuries]; 1.85 megabecquerels [50 microcuries]; 3.7 megabecquerels [100 microcuries]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule [therapeutic]: 28-3700 megabecquerels [0.75-100 millicuries]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Iodotope&reg;: 37-4810 megabecquerels [1-130 millicuries]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kit [therapeutic]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hicon&trade; 9.25 gigabecquerels (250 millicuries):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Capsule: Dibasic sodium phosphate 300 mg (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Capsule: Empty large gelatin capsule (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Solution: Sodium iodide I",
"     <sup>",
"      131",
"     </sup>",
"     9.25 gigabecquerels (250 millicuries) per 0.25 mL (0.25 mL) [contains edetate disodium, sodium thiosulphate and dibasic sodium phosphate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hicon&trade; 18.5 gigabecquerels (250 millicuries):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Capsule: Dibasic sodium phosphate 300 mg (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Capsule: Empty large gelatin capsule (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Solution: Sodium iodide I",
"     <sup>",
"      131",
"     </sup>",
"     18.5 gigabecquerels (500 millicuries) per 0.5 mL (0.5 mL) [contains edetate disodium, sodium thiosulphate and dibasic sodium phosphate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hicon&trade; 37 gigabecquerels (1000 millicuries):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Capsule: Dibasic sodium phosphate 300 mg (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Capsule: Empty large gelatin capsule (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Solution: Sodium iodide I",
"     <sup>",
"      131",
"     </sup>",
"     37 gigabecquerels (1000 millicuries) per 1 mL (1 mL) [contains edetate disodium, sodium thiosulphate and dibasic sodium phosphate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution [therapeutic]: 129.5-5550 megabecquerels per vial [3.5-150 millicuries per vial; contains sodium bisulfite and edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2521694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2522220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Waterproof gloves should be worn while handling and administering sodium iodide I",
"     <sup>",
"      131",
"     </sup>",
"     . Hicon&trade; must be diluted prior to administration. Ensure adequate hydration before and after treatment. Adhere to radiation safety precautions regarding radioactive iodine treatment.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2521699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For diagnostic use with the radioactive iodide (RAI) uptake test to evaluate thyroid function; treatment of hyperthyroidism and select cases of thyroid cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13320725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Graves&rsquo; disease; toxic multinodular goiter; toxic thyroid adenoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15245847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2521721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined, dose dependent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Chest pain, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Alopecia, itching, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Acute thyroid crisis, infertility (transient; may be permanent in males with repeated or high dose), thyroiditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea (high dose used in treatment of thyroid cancer), sialoadenitis (high dose used in treatment of thyroid cancer), sore throat, swallowing pain, taste (metallic), taste (unpleasant), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Anemia, blood dyscrasia, leukopenia, myelosuppression (high dose used in treatment of thyroid cancer), thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Neck tenderness/swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchospasm, cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, chromosomal abnormalities, hypersensitivity reactions, immunosuppression, radiation sickness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Neoplasm (rare; causative role not established)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2521705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodine or any component of the formulation; pre-existing vomiting and diarrhea (treatment); concurrent antithyroid medication (Hicon&trade;); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2521706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism/thyrotoxic cardiac disease: May be aggravated by radiation thyroiditis; consider pre- and post-treatment with antithyroid agents and/or beta-blockers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypochloremia: May increase thyroid uptake of sodium iodide I",
"     <sup>",
"      131",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; risk of adverse reactions may be increased. Nephrosis may increase thyroid uptake of sodium iodide I",
"     <sup>",
"      131",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodine/thyroid medications: Concomitant use of iodine, thyroid, or antithyroid medications may interfere with the uptake of radioiodide; medications should be discontinued for an appropriate time prior to dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients &lt;30 years of age: Use is not generally recommended for treatment of hyperthyroidism in patients &lt;30 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium bisulfite: Some dosage forms may contain sodium bisulfite which may cause allergic reactions in some individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Patients should be adequately hydrated prior to dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced staff: Should only be used by nuclear physicians and/or radiopharmacists qualified and experienced in use and handling of radionuclides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients must be instructed in measures to minimize exposure of others.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antithyroid Agents: May diminish the therapeutic effect of Sodium Iodide I131. Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: May diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2521700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2521701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iodine-131 crosses the placenta and may cause severe and irreversible hypothyroidism in neonates. Pregnancy should be ruled out prior to therapy. Effective contraception is recommended for 12 months following treatment for cancer, 6-12 months following treatment for hyperthyroidism.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2521703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2521704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast milk concentrations may be equal to or greater than maternal plasma levels. The Society of Nuclear Medicine guidelines suggest breast-feeding for that child be discontinued permanently.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2521728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some dietary sources of iodine include cow's milk and dairy products, fish, seaweed, eggs, chocolate, and iodized salt.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2522212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Readily absorbed following oral administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Extracellular fluid; primarily trapped by the thyroid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Iodide is rapidly oxidized to iodine in the thyroid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (37% to 75%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Breast Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108:776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1685/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, &ldquo;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&rdquo;",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1685/abstract-text/ 21510801/pubmed\" id=\" 21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meier DA, Brill DR, Becker DV, et al, &ldquo;Procedure Guideline for Therapy of Thyroid Disease With (131)Iodine,&rdquo;",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 2002, 43(6):856-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1685/abstract-text/12050333/pubmed\" id=\"12050333\" target=\"_blank\">",
"        12050333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10276 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-ADE281C057-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1685=[""].join("\n");
var outline_f1_41_1685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521692\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521696\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522218\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317074\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522219\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522262\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521694\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522220\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521699\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13320725\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245847\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521721\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521705\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521706\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300058\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223000\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521700\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521701\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521703\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521704\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521728\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522212\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10276\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10276|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/7/15476?source=related_link\">",
"      Sodium iodide I-131: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_41_1686="Trace metals: Pediatric drug information";
var content_f1_41_1686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trace metals: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/40/34435?source=see_link\">",
"    see \"Trace metals: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/32/6659?source=see_link\">",
"    see \"Trace metals: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Multitrace&reg;-4;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Concentrate;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Neonatal;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Pediatric;",
"     </li>",
"     <li>",
"      Multitrace&reg;-5;",
"     </li>",
"     <li>",
"      Multitrace&reg;-5 Concentrate;",
"     </li>",
"     <li>",
"      Trace Elements 4 Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Trace Element, Multiple, Neonatal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Trace Element, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      ASPEN Guidelines: Trace Mineral Daily Requirements",
"      <sup>",
"       1",
"      </sup>",
"      (Mirtallo, 2004)",
"     </caption>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Preterm Neonates (&lt;3 kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Term Neonates (3-10 kg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Recommended intakes of trace elements",
"         <b>",
"          cannot",
"         </b>",
"         be achieved through the use of a commercially available combination trace element product. Only through the use of individualized trace element products can recommended intakes be achieved.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Reduce dose in patients with renal dysfunction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Reduce dose by 50% in patients with impaired biliary excretion or cholestatic liver disease.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Omit in patients with impaired biliary excretion or cholestatic liver disease.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          5",
"         </sup>",
"         Indicated for use in long-term parenteral nutrition patients.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Chromium",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.05-0.2 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.2 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Copper",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Manganese",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Selenium",
"         <sup>",
"          2,5",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.5-2 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Zinc",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-250 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Table has been converted to the following text:",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      ASPEN Guidelines: Trace Mineral Daily Requirements",
"      <sup>",
"       1",
"      </sup>",
"      (Mirtallo, 2004):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     <sup>",
"      1",
"     </sup>",
"     Recommended intakes of trace elements",
"     <b>",
"      cannot",
"     </b>",
"     be achieved through the use of a commercially available combination trace element product. Only through the use of individualized trace element products can recommended intakes be achieved.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Chromium:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Reduce dose in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Preterm neonates (&lt;3 kg): 0.05-0.2 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Term neonates (3-10 kg): 0.2 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Copper:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Reduce dose by 50% in patients with impaired biliary excretion or cholestatic liver disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Preterm neonates (&lt;3 kg): 20 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Term neonates (3-10 kg): 20 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Manganese:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Omit in patients with impaired biliary excretion or cholestatic liver disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Preterm neonates (&lt;3 kg): 1 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Term neonates (3-10 kg): 1 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Selenium:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Reduce dose in patients with renal dysfunction; indicated for use in long-term parenteral nutrition patients",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Preterm neonates (&lt;3 kg): 1.5-2 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Term neonates (3-10 kg): 2 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Zinc:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Preterm neonates (&lt;3 kg): 400 mcg/kg",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Term neonates (3-10 kg): 50-250 mcg/kg",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/40/34435?source=see_link\">",
"      see \"Trace metals: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      ASPEN Guidelines: Trace Mineral Daily Requirements",
"      <sup>",
"       1",
"      </sup>",
"      (Mirtallo, 2004)",
"     </caption>",
"     <col align=\"left\" width=\"115\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"left\">",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Infants 3-10 kg",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Infants, Children, and Adolescents 10-40 kg",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adolescents &gt;40 kg",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Recommended intakes of trace elements",
"         <b>",
"          cannot",
"         </b>",
"         be achieved through the use of a commercially available combination trace element product. Only through the use of individualized trace element products can recommended intakes be achieved.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Reduce dose in patients with renal dysfunction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Reduce dose by 50% in patients with impaired biliary excretion or cholestatic liver disease.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Omit in patients with impaired biliary excretion or cholestatic liver disease.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          5",
"         </sup>",
"         Indicated for use in long-term parenteral nutrition patients.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Chromium",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.2 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.14-0.2 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-15 mcg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Copper",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-20 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200-500 mcg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Manganese",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40-100 mcg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Selenium",
"         <sup>",
"          2,5",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-2 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40-60 mcg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Zinc",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-250 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-125 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-5",
"         <b>",
"          mg",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Adults:",
"     <b>",
"      Recommended daily parenteral dosage: Manufacturer labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Chromium: 10-15 mcg; use caution in renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Copper: 0.5-1.5",
"     <b>",
"      mg",
"     </b>",
"     ; decrease dose or omit in patients with severe liver dysfunction and/or biliary tract obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Manganese: 150-800 mcg; decrease dose or omit in patients with severe liver dysfunction and/or biliary tract obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Selenium: 20-40 mcg; decrease dose or omit in patients with renal dysfunction and/or gastrointestinal malfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Zinc: 2.5-4",
"     <b>",
"      mg",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [combination products]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-4: Chromium 4 mcg, copper 0.4 mg, manganese 0.1 mg, and zinc 1 mg per 1 mL (10 mL) [contains aluminum, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-4 Concentrate: Chromium 10 mcg, copper 1 mg, manganese 0.5 mg, and zinc 5 mg per 1 mL (1 mL) [contains aluminum]; chromium 10 mcg, copper 1 mg, manganese 0.5 mg, and zinc 5 mg per 1 mL (10 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-4 Neonatal: Chromium 0.85 mcg, copper 0.1 mg, manganese 0.025 mg, and zinc 1.5 mg per 1 mL (2 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-5: Chromium 4 mcg, copper 0.4 mg, manganese 0.1 mg, selenium 20 mcg, and zinc 1 mg per 1 mL (10 mL) [contains aluminum, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-5 Concentrate: Chromium 10 mcg, copper 1 mg, manganese 0.5 mg, selenium 60 mcg, and zinc 5 mg per 1 mL (1 mL) [contains aluminum]; chromium 10 mcg, copper 1 mg, manganese 0.5 mg, selenium 60 mcg, and zinc 5 mg per 1 mL (10 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trace Elements 4 Pediatric: Chromium 1 mcg, copper 0.1 mg, manganese 0.03 mg, and zinc 0.5 mg per 1 mL (10 mL) [contains aluminum, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [combination products, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-4 Pediatric: Chromium 1 mcg, copper 0.1 mg, manganese 0.025 mg, and zinc 1 mg per 1 mL (3 mL) [contains aluminum]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Must be diluted prior to use and infused as component of parenteral nutrition or parenteral solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevent and correct trace metal deficiencies (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to a specific trace metal or component of the trace metal solution; do not give undiluted, direct injection due to potential for phlebitis and tissue irritation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     The parenteral product contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metals may accumulate in conditions of renal failure or biliary obstruction; consider reduction in dosage or deletion of copper and manganese in patients with biliary obstruction; avoid copper use in patients with Wilson's disease; administration of copper in the absence of zinc or zinc in the absence of copper may cause decreases in their respective plasma levels; multiple trace metal solutions present a risk of overdosage when the need for one trace element is appreciably higher than for others in the formulation; utilization of individual trace metal solutions may be needed. Consider reduction in dosage or deletion of selenium and chromium in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some products contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites; use benzyl alcohol-containing products with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual elements for requirements in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1062655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chromium: 0.18-0.47 ng/mL (SI: 35-90 nmol/L); some laboratories report much higher",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Copper: &sim;0.7-1.5 mcg/mL (SI: 11-24 micromoles/L); levels are higher in pregnant women and children; Note: May not be a meaningful measurement of body stores.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manganese: 18-30 mcg/dL (SI: 2.3-3.8 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Selenium: 95-165 ng/mL (SI: 120-209 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Zinc: 70-120 mcg/dL (SI: 10-18.4 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chromium: Part of glucose tolerance factor, an essential activator of insulin-mediated reactions; helps maintain normal glucose metabolism and peripheral nerve function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Copper: Cofactor for serum ceruloplasmin, helps maintain normal rates of red and white cell formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manganese: Activator for several enzymes including manganese-dependent superoxide dismutase and pyruvate carboxylase; activates glycosyl transferases involved in mucopolysaccharide synthesis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Selenium: Part of glutathione peroxidase which protects cell components from oxidative damage due to peroxides produced in cellular metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Zinc: A cofactor for &gt;70 different enzymes; facilitates wound healing, helps maintain normal growth rates, normal skin hydration, and the senses of taste and smell",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chromium: 10% to 20% oral absorption; excretion primarily via kidneys and bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Copper: 30% oral absorption; 80% elimination via bile; intestinal wall 16% and urine 4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manganese: 10% oral absorption; excretion primarily via bile; ancillary routes via pancreatic secretions or reabsorption into the intestinal lumen occur during periods of biliary obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Selenium: Very poor oral absorption; 75% excretion via kidneys, remainder via feces, lung, and skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Zinc: 20% to 30% oral absorption; 90% excretion in stools, remainder via urine and perspiration",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following describe the symptomatology associated with excess trace elements:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chromium: Nausea, vomiting, GI ulcers, renal and hepatic dysfunction, convulsions, coma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Copper: Prostration, behavioral changes, diarrhea, progressive marasmus, hypotonia, photophobia, hepatic dysfunction, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Manganese: Irritability, speech disturbances, abnormal gait, headache, anorexia, apathy, impotence, cholestatic jaundice, movement disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selenium: Alopecia, weak nails, dermatitis, dental defects, GI disorders, nervousness, mental depression, metallic taste, garlic odor of breath and sweat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc: Profuse diaphoresis, consciousness decreased, blurred vision, tachycardia, hypothermia",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carney LN, Nepa A, Cohen SS, et al, &ldquo;Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds, The A.S.P.E.N Pediatric Nutrition Support Core Curriculum, Silver Spring, MD: American Society of Parenteral and Enteral Nutrition, 2010, 440-1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlstrom KA, Ament ME, Medhin MG, et al, \"Serum Trace Elements in Children Receiving Long-Term Parenteral Nutrition,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1986, 109(4):625-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1686/abstract-text/3093658/pubmed\" id=\"3093658\" target=\"_blank\">",
"        3093658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department Health and Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fell JM, Reynolds AP, Meadows N, et al, \"Manganese Toxicity in Children Receiving Long-Term Parenteral Nutrition,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1996, 347(9010):1218-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1686/abstract-text/8622451/pubmed\" id=\"8622451\" target=\"_blank\">",
"        8622451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greene HL, Hambridge KM, Schanler R, et al, \"Guidelines for the Use of Vitamins, Trace Elements, Calcium, Magnesium and Phosphorus in Infants and Children Receiving Total Parenteral Nutrition: Report of the Subcommittee on Pediatric Nutrient Requirements From the Committee on Clinical Practice Issues of The American Society for Clinical Nutrition,\"",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 1988, 48(5):1324-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1686/abstract-text/ 3142247 /pubmed\" id=\" 3142247 \" target=\"_blank\">",
"        3142247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litov RE and Combs GF Jr, \"Selenium in Pediatric Nutrition,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1991, 87(3):339-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1686/abstract-text/2000274/pubmed\" id=\"2000274\" target=\"_blank\">",
"        2000274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, \"Safe Practices for Parenteral Nutrition,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1686/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12853 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1686=[""].join("\n");
var outline_f1_41_1686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062652\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675769\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062649\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229564\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229556\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062657\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062656\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062660\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062648\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062647\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229561\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287124\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062655\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062646\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062659\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062661\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12853\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12853|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/40/34435?source=related_link\">",
"      Trace metals: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/32/6659?source=related_link\">",
"      Trace metals: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_41_1687="TEE transverse view of aortic rupture";
var content_f1_41_1687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76283%7ECARD%2F76883%7ECARD%2F63952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76283%7ECARD%2F76883%7ECARD%2F63952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography transverse view of aortic rupture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transesophageal echocardiography transverse view&nbsp;of traumatic subadventitial rupture of the aortic isthmus. There is a thick and highly mobile medial flap associated with a localized deformity of the anterolateral aortic wall due to the acute formation of a pseudoaneurysm (small arrow). The flap is thicker than the intimal flap seen with aortic dissection, since the entire depth of the intima and media are involved with aortic rupture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD and RM Lang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography transverse view of a traumatic rupture of the aortic isthmus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The subadventitial aortic disruption was associated with the presence of a thick \"medial flap\" (arrow) and a localized deformity of the aortic wall due to the acute formation of a false aneurysm (arrowheads).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography longitudinal view of a traumatic rupture of the aortic isthmus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thick \"medial flap\" (arrow) was almost perpendicular to aortic walls because the injury was confined within a few centimeters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1687=[""].join("\n");
var outline_f1_41_1687=null;
var title_f1_41_1688="Ofloxacin (systemic): Drug information";
var content_f1_41_1688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ofloxacin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=see_link\">",
"    see \"Ofloxacin (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/28/34246?source=see_link\">",
"    see \"Ofloxacin (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9496286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9496295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oflox&reg;;",
"     </li>",
"     <li>",
"      Novo-Ofloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9498132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Quinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9497845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervicitis/urethritis (nongonococcal):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Nongonococcal:",
"     </i>",
"     300 mg every 12 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Gonococcal (acute, uncomplicated):",
"     </i>",
"     400 mg as a single dose;",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of uncomplicated gonococcal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic bronchitis (acute exacerbation), community-acquired pneumonia, skin and skin structure infections (uncomplicated):",
"     </b>",
"     Oral: 400 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Epididymitis, nongonococcal (unlabeled use):",
"     </b>",
"     Oral: 300 mg twice daily for 10 days (CDC, 2010); 200 mg twice daily for 14 days (Canadian STI Guidelines, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Leprosy (unlabeled use):",
"     </b>",
"     Oral: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease (acute):",
"     </b>",
"     Oral: 400 mg every 12 hours for 10-14 days;",
"     <b>",
"      Note:",
"     </b>",
"     The CDC recommends use only if standard cephalosporin therapy is not feasible and community prevalence of quinolone-resistant gonococcal organisms is low. Culture sensitivity must be confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prostatitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute:",
"     </i>",
"     400 mg for 1 dose, then 300 mg twice daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic:",
"     </i>",
"     200 mg every 12 hours for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Traveler's diarrhea (unlabeled use):",
"     </b>",
"     Oral: 300 mg twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      UTI:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Uncomplicated:",
"     </i>",
"     200 mg every 12 hours for 3-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Complicated:",
"     </i>",
"     200 mg every 12 hours for 10 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9497846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 200-400 mg every 12-24 hours (based on estimated renal function) for 7 days to 6 weeks depending on indication.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9497847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: After a normal initial dose, adjust as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-50 mL/minute: Administer usual dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer half the usual dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venovenous hemodiafiltration effects: Administer 300 mg every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9497848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe impairment: Maximum dose: 400 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9497986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 300 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9496347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9496293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088599.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088599.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9497866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Do not take within 2 hours of food or any antacids which contain zinc, magnesium, or aluminum.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9496348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Quinolone antibiotic for the treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia, skin and skin structure infections (uncomplicated), urethral and cervical gonorrhea (acute, uncomplicated), urethritis and cervicitis (nongonococcal), mixed infections of the urethra and cervix, pelvic inflammatory disease (acute), cystitis (uncomplicated), urinary tract infections (complicated), prostatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of gonococcal disease.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9496353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epididymitis (nongonococcal), leprosy, Traveler's diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9497560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 9%), insomnia (3% to 7%), dizziness (1% to 5%), fatigue (1% to 3%), somnolence (1% to 3%), sleep disorders (1% to 3%), nervousness (1% to 3%), pyrexia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash/pruritus (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1% to 4%), vomiting (1% to 4%), GI distress (1% to 3%), abdominal cramps (1% to 3%), flatulence (1% to 3%), abnormal taste (1% to 3%), xerostomia (1% to 3%), appetite decreased (1% to 3%), nausea (3% to 10%), constipation (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (1% to 5%), external genital pruritus in women (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbances (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Trunk pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Anaphylaxis reactions, anxiety, blurred vision, chills, cognitive change, cough, depression, dream abnormality, ecchymosis, edema, erythema nodosum, euphoria, extremity pain, hallucinations, hearing acuity decreased, hepatic dysfunction, hepatic failure (some fatal), hepatitis, hyper-/hypoglycemia, hypertension, interstitial nephritis, intracranial pressure increased, lightheadedness, malaise, myasthenia gravis exacerbation, palpitation, paresthesia, peripheral neuropathy, photophobia, photosensitivity, pneumonitis, pseudotumor cerebri, psychotic reactions, rhabdomyolysis, seizure, Stevens-Johnson syndrome, syncope, tendonitis and tendon rupture, thirst, tinnitus, torsade de pointes, Tourette's syndrome, toxic epidermal necrolysis, vasculitis, vasodilation, vertigo, weakness, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9497548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ofloxacin or other members of the quinolone group, such as oxolinic acid, cinoxacin, norfloxacin, and ciprofloxacin; hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9497549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Fluoroquinolones may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; avoid use in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Tremor, restlessness, confusion, and very rarely hallucinations, increased intracranial pressure (including pseudotumor cerebri) or seizures may occur; use with caution in patients with known or suspected CNS disorder. Discontinue in patients who experience significant CNS adverse effects (eg, dizziness, hallucinations, suicidal ideations or actions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as s systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: The use of quinolones has been linked to peripheral neuropathy (rare); discontinue if symptoms of sensory or sensorimotor neuropathy occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tendon inflammation/rupture:",
"     <b>",
"      [U.S. Boxed Warning]: There have been reports of tendon inflammation and/or rupture with quinolone antibiotics; risk may be increased with concurrent corticosteroids, organ transplant recipients, and in patients &gt;60 years of age.",
"     </b>",
"     Rupture of the Achilles tendon sometimes requiring surgical repair has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps) have also been reported. Strenuous physical activity may be an independent risk factor for tendonitis. Discontinue at first sign of tendon inflammation or pain. May occur even after discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis:",
"     <b>",
"      [U.S. Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis.",
"     </b>",
"     Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported; avoid use in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in individuals at risk of seizures (CNS disorders or concurrent therapy with medications which may lower seizure threshold). Potential for seizures, although very rare, may be increased with concomitant NSAID therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syphilis: Since ofloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9497653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9497654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Quinolone Antibiotics may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9497658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Ofloxacin average peak serum concentrations may be decreased by 20% if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9496354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9496355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies ofloxacin as pregnancy category C. Ofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid. An increased risk of teratogenic effects has not been observed in animals or humans following ofloxacin use during pregnancy; however, because of concerns of cartilage damage in immature animals, ofloxacin should only be used during pregnancy if a safer option is not available. Serum concentrations of ofloxacin may be lower during pregnancy than in nonpregnant patients.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9497525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9497547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ofloxacin is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. Due to the low concentrations in human milk, minimal toxicity would be expected in the nursing infant. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9497988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ofloxacin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (50): $239.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (50): $284.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $600.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15577087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC, renal and hepatic function periodically if therapy is prolonged.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Akilen (ID, SG);",
"     </li>",
"     <li>",
"      Boravid (IE);",
"     </li>",
"     <li>",
"      Danoflox (ID);",
"     </li>",
"     <li>",
"      Evaflox (MY);",
"     </li>",
"     <li>",
"      Flobacin (IT);",
"     </li>",
"     <li>",
"      Flotavid (ID);",
"     </li>",
"     <li>",
"      Flovid (HK, PH, SG);",
"     </li>",
"     <li>",
"      Floxil (AR);",
"     </li>",
"     <li>",
"      Floxstat (BB, BM, BS, CO, EC, GY, JM, NL, PR, SR, TT, VE);",
"     </li>",
"     <li>",
"      Hyflox (TH);",
"     </li>",
"     <li>",
"      Kinflocin (TW);",
"     </li>",
"     <li>",
"      Kinoxacin (KP);",
"     </li>",
"     <li>",
"      Loxinter (ID);",
"     </li>",
"     <li>",
"      Medofloxine (MY);",
"     </li>",
"     <li>",
"      Mefoxa (ID);",
"     </li>",
"     <li>",
"      Novecin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nufafloqo (ID);",
"     </li>",
"     <li>",
"      Occidal (TH);",
"     </li>",
"     <li>",
"      Ofcin (MY, TH, TW);",
"     </li>",
"     <li>",
"      Oflin (IN);",
"     </li>",
"     <li>",
"      Oflocee (TH);",
"     </li>",
"     <li>",
"      Oflocet (FR, NZ, PT);",
"     </li>",
"     <li>",
"      Oflocin (IT);",
"     </li>",
"     <li>",
"      Oflodal (TW);",
"     </li>",
"     <li>",
"      Oflodex (IL);",
"     </li>",
"     <li>",
"      Oflodura (DE);",
"     </li>",
"     <li>",
"      Ofloxin (CZ, EE, TH);",
"     </li>",
"     <li>",
"      Ofloxol (MY);",
"     </li>",
"     <li>",
"      Oltrex (GT);",
"     </li>",
"     <li>",
"      Onexacin (PH);",
"     </li>",
"     <li>",
"      Orivid (TH);",
"     </li>",
"     <li>",
"      Orocin (KP);",
"     </li>",
"     <li>",
"      Oxacin (TW);",
"     </li>",
"     <li>",
"      Pharflox (ID);",
"     </li>",
"     <li>",
"      Qinolon (PH);",
"     </li>",
"     <li>",
"      Quotavil (HK);",
"     </li>",
"     <li>",
"      Rilox (ID);",
"     </li>",
"     <li>",
"      Sinflo (TW);",
"     </li>",
"     <li>",
"      Tabrin (GR);",
"     </li>",
"     <li>",
"      Tafloc (ZA);",
"     </li>",
"     <li>",
"      Taravid (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tariflox (ID);",
"     </li>",
"     <li>",
"      Tarivid (AT, BE, BF, BJ, CH, CI, CL, DK, EE, ET, FI, GB, GH, GM, GN, HN, ID, IE, IL, IN, JP, KE, KP, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NO, PK, PL, PT, RU, SC, SD, SE, SG, SK, SL, SN, TH, TN, TR, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Uro Tarivid (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Vioflox (KP);",
"     </li>",
"     <li>",
"      Vioson (PH);",
"     </li>",
"     <li>",
"      Viotisone (TH);",
"     </li>",
"     <li>",
"      Zanocin (IN, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9497678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ofloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9497680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; food causes only minor alterations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.4-3.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: 4-5 hours and 20-25 hours (accounts for &lt;5%); prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Guidelines on Sexually Transmitted Infections, \"Epididymitis,\" 2008; Ottawa, ON: Public Health Agency of Canada. Available at file://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(14):332-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/17431378/pubmed\" id=\"17431378\" target=\"_blank\">",
"        17431378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(12):1807-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/15585448/pubmed\" id=\"15585448\" target=\"_blank\">",
"        15585448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frothingham R, &ldquo;Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1269-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/16206101/pubmed\" id=\"16206101\" target=\"_blank\">",
"        16206101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gavin JR 3rd, Kubin R, Choudhri S, et al, &ldquo;Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2004, 27(9):671-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/15230648/pubmed\" id=\"15230648\" target=\"_blank\">",
"        15230648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giamarellou H, Kolokythas E, Petrikkos G, et al, &ldquo;Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1989, 87(Suppl 5A):49-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graumlich JF, Habis S, Avelino RR, et al, &ldquo;Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/16185172/pubmed\" id=\"16185172\" target=\"_blank\">",
"        16185172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobs MR, Felmingham D, Appelbaum PC, et al, &ldquo;The Alexander Project 1998-2000: Susceptibility of Pathogens Isolated From Community-Acquired Respiratory Tract Infection to Commonly Used Antimicrobial Agents,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2003, 52(2):229-46.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(11):1404-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/12766835/pubmed\" id=\"12766835\" target=\"_blank\">",
"        12766835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawrence KR, Adra M, and Keir C, &ldquo;Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin,&rdquo;",
"      <i>",
"       J Infect",
"      </i>",
"      , 2006, 52(6):e177-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/16269178/pubmed\" id=\"16269178\" target=\"_blank\">",
"        16269178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loebstein R, Addis A, Ho E, et al, &ldquo;Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1998, 42(6):1336-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/9624471/pubmed\" id=\"9624471\" target=\"_blank\">",
"        9624471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(10):2949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/11557500/pubmed\" id=\"11557500\" target=\"_blank\">",
"        11557500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1303-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/16185173/pubmed\" id=\"16185173\" target=\"_blank\">",
"        16185173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nilsson-Ehle I and Ljungberg B, &ldquo;Quinolone Disposition in the Elderly: Practical Implications,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1991, 1(4):279-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/1794020/pubmed\" id=\"1794020\" target=\"_blank\">",
"        1794020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park-Wyllie LY, Juurlink DN, Kopp A, et al, &ldquo;Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(13):1352-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/16510739/pubmed\" id=\"16510739\" target=\"_blank\">",
"        16510739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peled Y, Friedman S, Hod M, et al, &ldquo;Ofloxacin During the Second Trimester of Pregnancy,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(11):1181-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/1763532/pubmed\" id=\"1763532\" target=\"_blank\">",
"        1763532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(3):193.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thalhammer F, Kletzmayr J, El Menyawi I, et al, &ldquo;Ofloxacin Clearance During Hemodialysis: A Comparison of Polysulfone and Cellulose Acetate Hemodialyzers,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 1998, 32(4):642-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/9774127/pubmed\" id=\"9774127\" target=\"_blank\">",
"        9774127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang S and Rizvi AA, &ldquo;Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 2006, 331(6):334-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/16775443/pubmed\" id=\"16775443\" target=\"_blank\">",
"        16775443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/41/1688/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9892 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1688=[""].join("\n");
var outline_f1_41_1688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496286\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496295\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9498132\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497845\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497846\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497847\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497848\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497986\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496347\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496293\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497866\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496348\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496353\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497560\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497548\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497549\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497653\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497654\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497658\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496354\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496355\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497525\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497547\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497988\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15577087\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961995\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497678\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497680\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9892\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9892|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=related_link\">",
"      Ofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30020?source=related_link\">",
"      Ofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21363?source=related_link\">",
"      Ofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=related_link\">",
"      Ofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16484?source=related_link\">",
"      Ofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/42/20131?source=related_link\">",
"      Ofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=related_link\">",
"      Ofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/28/34246?source=related_link\">",
"      Ofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_41_1689="Wheezing illnesses other than asthma in children";
var content_f1_41_1689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Wheezing illnesses other than asthma in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/41/1689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/41/1689/contributors\">",
"     Khoulood Fakhoury, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/41/1689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/41/1689/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/41/1689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/41/1689/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/41/1689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wheezing is a common presenting symptom of respiratory disease in children. A nationwide survey in the United States between 1988 and 1994 showed that the prevalence for wheezing amongst 2 to 3 year olds was 26 percent and amongst 9 to 11 years was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/1\">",
"     1",
"    </a>",
"    ]. A wide range of prevalence of wheeze is observed between and within countries over time. Between 1994 to 1996, for example, the UK had the highest recorded prevalence of wheezing (31 percent) and Ethiopia the lowest (1.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wheezing can be divided clinically according to the acuity of its onset and the mechanism of airway narrowing. In addition to asthma, new onset acute wheezing suggests infection or sudden airway obstruction, whereas chronic or recurrent wheezes may be caused by congenital abnormalities, cardiac disease, aspiration syndromes, impaired immunologic defenses, or underlying pulmonary disease.",
"   </p>",
"   <p>",
"    One in three children experience at least one acute wheezing illness before the age of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Most infants and young children with recurrent wheezing probably have asthma. However, a wide variety of congenital and acquired conditions can cause narrowing of the extrathoracic or intrathoracic airways, and may present with wheezing (",
"    <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"     table 1",
"    </a>",
"    ). An overview of the causes of nonasthmatic wheezing in children is presented here.",
"   </p>",
"   <p>",
"    A diagnostic approach to wheezing (including the definition and physiology of wheezing) and an overview of the diagnosis and management of asthma are presented separately. The emergent evaluation of children with acute respiratory distress is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE WHEEZING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to asthma, acute onset of wheezing in a child is most often caused by an infectious process or foreign body aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interrelationship of viral infection, wheezing, and the development of asthma in children is complex and changes according to the patient's age, the presence of atopy, and environmental factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"     \"Risk factors for asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"     \"Virus-induced wheezing and asthma: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants younger than two years of age, the most common cause of acute wheezing is viral bronchiolitis, which can be caused by a variety of viruses, the most common of which is respiratory syncytial virus (RSV). Infection caused by other paramyxoviruses, including parainfluenza virus and metapneumovirus, also can result in wheezing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=see_link\">",
"     \"Bronchiolitis in infants and children: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H10#H10\">",
"     \"Parainfluenza viruses in children\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link&amp;anchor=H15#H15\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The affected patient typically presents with a history of runny nose, cough, and intermittent fever. These changes are followed by wheezing, which commonly is associated with tachypnea and shortness of breath. Physical examination usually reveals nasal congestion, tachypnea, increased work of breathing, and polyphonic wheezes throughout the lungs. Hypovolemia and dehydration may result from increased insensible losses caused by tachypnea and fever, in combination with decreased oral intake.",
"   </p>",
"   <p>",
"    Chest radiographs can be normal. However, some reveal hyperinflation with peribronchial thickening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parenchymal disease with infiltrates or atelectasis.",
"   </p>",
"   <p>",
"    Rapid antigen detection, ELISA-based assays, and polymerase chain reaction (PCR) are available for several of the common respiratory viruses and do not require the time or technical expertise necessary for viral cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=see_link&amp;anchor=H26#H26\">",
"     \"Bronchiolitis in infants and children: Clinical features and diagnosis\", section on 'Virologic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other less common infections can be associated with acute wheezing. They include bacterial tracheitis, acute laryngotracheobronchitis, epiglottitis, acute bronchitis, Mycoplasma pneumonia, and peritonsillar, retropharyngeal, or lung abscesses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link&amp;anchor=H4#H4\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Infectious etiologies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link\">",
"     \"Clinical features, evaluation, and diagnosis of croup\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link&amp;anchor=H13#H13\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\", section on 'Symptoms and signs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H5#H5\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Foreign body aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign body aspiration (FBA) should be suspected in any patient who presents with wheezing of sudden onset, even in the absence of a clear history of a choking episode. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed history regarding the circumstances surrounding the onset of wheezing is crucial when FBA is suspected. A history of choking is highly suggestive of FBA, but it is not witnessed or recalled in all cases. FBA is more common in young children, although it is seen less commonly in infants under six months of age, presumably because these infants are less likely to have easy access to small objects that may be aspirated.",
"   </p>",
"   <p>",
"    Physical examination can provide clues to the diagnosis of FBA. Foreign body aspiration should be suspected in any child with a unilateral wheeze or unequal breath sounds. In children, unlike adults, the foreign body can lodge in any bronchus, without predilection to the right side. Occasionally, the foreign body may trigger a generalized irritant response and diffuse polyphonic wheezes may be present.",
"   </p>",
"   <p>",
"    Chest radiographs that demonstrate localized hyperinflation or atelectasis are consistent with FBA, although other causes include asthma and bronchiolitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76951 graphicRef55279 \" href=\"UTD.htm?25/34/26147\">",
"     image 1A-B",
"    </a>",
"    ). Inspiratory and expiratory chest radiographs can help identify air trapping. However, absence of these findings does not exclude the diagnosis. In general, patients with FBA do not respond to bronchodilator therapy.",
"   </p>",
"   <p>",
"    Esophageal foreign body can present with acute wheezing secondary to compression of the airways. A history of feeding and swallowing difficulties and the presence of dysphagia are important clues to the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHRONIC OR RECURRENT WHEEZING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of wheezing that is chronic or episodic is broad and includes structural abnormalities of the tracheobronchial tree or other thoracic structures. Nonstructural causes of chronic wheezing include aspiration syndromes, bronchopulmonary dysplasia, vocal cord dysfunction, and abnormal immunologic defense mechanisms (",
"    <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Structural causes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Anomalies of the tracheobronchial tree",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital tracheomalacia and bronchomalacia can present with noisy breathing early in life. Parents commonly describe the child as \"being born with a cold\" [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/5\">",
"     5",
"    </a>",
"    ]. Wheezing can present at birth, but more commonly becomes apparent in the first two to three months after birth. The wheezing usually is monophonic and becomes more pronounced with activity or in the setting of upper respiratory tract infections. Other symptoms can include a croup-like cough or stridor, depending upon the location of the lesion. The severity can vary from a thriving child with noisy breathing to a child with severe respiratory distress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=see_link\">",
"     \"Apparent life-threatening event in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of a patient with a suspected primary tracheobronchial anomaly should begin with plain chest radiographs. These are often nondiagnostic, but will rule out other causes of wheezing, particularly mediastinal masses and cardiomegaly. Fluoroscopy of the airways may identify dynamic collapse that is more pronounced during expiration. The historical approach was to perform",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow if a vascular ring was suspected. This has now been replaced in most centers by CT angiogram or magnetic resonance imaging with contrast (magnetic resonance angiography, MRA) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/6\">",
"     6",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) or CT can also identify foregut anomalies (eg, tracheoesophageal fistula and esophageal atresia). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Cardiovascular disease'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Aspiration syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Computed tomography of the chest can also detect narrowing or compression of the central airways. However, bronchoscopy (during spontaneous breathing) is usually required to make a definitive diagnosis. Malacia can be identified by the presence of exaggerated collapse of the airways during expiration. Bronchoscopy also can be used to diagnose intraluminal obstruction or stenosis, or the presence of external compression, either by a pulsatile vessel or a nonpulsatile structure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of cardiovascular diseases can present with wheezing. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac conditions that result in pulmonary artery dilation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      left atrial enlargement, including large left to right shunts, can compress large airways and cause wheezing. In addition to compression of the mainstem bronchi by markedly enlarged central pulmonary arteries, compression of intrapulmonary bronchi by abnormally branching pulmonary arteries has been reported in patients with absent pulmonic valves [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathophysiology of left to right shunts\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Left ventricular failure or pulmonary venous outflow obstruction can result in distension of the pulmonary vascular bed, bronchiolar wall edema, increased airway resistance, and wheezing [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/10\">",
"       10",
"      </a>",
"      ]. Bronchial hyperresponsive was also reported in patients with congenital heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/11\">",
"       11",
"      </a>",
"      ]. One hypothesis is that pulmonary venous hypertension may cause hypertrophy of pulmonary veins, increase spasm of pulmonary vasculature and, as a final event, release vasoreactive substances that affect both vascular and bronchial smooth muscle reactivity, leading to a &ldquo;pseudoasthmatic&rdquo; state [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/12\">",
"       12",
"      </a>",
"      ]. In some infants with obstructed venous return, cardiac findings, including cardiomegaly and murmurs may be absent; therefore, a high index of suspicion is required to make the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/13\">",
"       13",
"      </a>",
"      ]. Wheezing was reported as the only presenting symptom in cases of isolated cor triatriatum [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/12,14\">",
"       12,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=see_link\">",
"       \"Pulmonary veno-occlusive disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vascular rings or slings can cause obstruction of large airways and may result in wheezing or stridor [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/6,9,15-17\">",
"       6,9,15-17",
"      </a>",
"      ]. These include complete (eg, double and right aortic arches) and incomplete (eg, pulmonary artery sling) rings. Pulmonary artery (PA) slings also can result in vascular compression of the airways. Hyperinflation or atelectasis of the right lung may be noted in patients with a pulmonary artery sling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"       \"Vascular rings\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Signs and symptoms of vascular compression of the airways commonly appear early in life. Biphasic stridor is the most common sign in these patients, but wheezing, respiratory distress, recurrent respiratory infections, and apnea also may be presenting findings. Patients may also have symptoms related to esophageal compression by vascular structures, including feeding difficulty and vomiting.",
"      <br/>",
"      <br/>",
"      Physical examination findings include loud, harsh wheezes during inspiration and expiration and hyperextension of the neck to improve patency of the airways. Signs and symptoms may be reproduced or exaggerated with neck flexion.",
"      <br/>",
"      <br/>",
"      The diagnostic evaluation of a child with a suspected vascular ring or sling begins with a plain chest radiograph, which is abnormal in the majority of cases. There is almost always a predominant right aortic arch with vascular rings. The common radiologic findings in patients with vascular airway compression are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef51295 \" href=\"UTD.htm?11/25/11675\">",
"       table 2",
"      </a>",
"      ). The next step in the diagnostic work-up may include a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      contrast esophagogram (barium swallow), magnetic resonance (MR) angiography, or computed tomography (CT). Bronchoscopy is not mandatory in all patients with a suspected or confirmed vascular ring. It is useful in confirming the location and severity of airway obstruction and in evaluating airway malacia. However, it cannot define the anatomy of a vascular ring and there is risk of causing tracheal edema, which may worsen tracheal obstruction. Nevertheless, it can be helpful for comparison of airway patency before and after surgery. The diagnostic approach is dependent upon the local expertise, experience, medical costs, and available technology at the medical center. Diagnosis and management of vascular rings are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link&amp;anchor=H14#H14\">",
"       \"Vascular rings\", section on 'Diagnosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      When a vascular ring is identified, cardiac evaluation should be pursued to rule out concomitant intracardiac abnormalities. Echocardiography is useful in delineating vascular anatomy as well as ruling out any associated cardiac defects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link&amp;anchor=H12#H12\">",
"       \"Vascular rings\", section on 'Associated anomalies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7432047\">",
"    <span class=\"h3\">",
"     Mediastinal masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mediastinal masses, including tumors, thymic lesions, bronchogenic cysts, angiomatous lesions, and enlarged lymph nodes, can cause compression of the trachea or bronchi, resulting in chronic cough and persistent or progressive wheeze. Cervical or supraclavicular lymphadenopathy is an important associated finding. The anatomic location of the mass within the mediastinum provides some clues to the underlying diagnosis (",
"    <a class=\"graphic graphic_figure graphicRef56637 \" href=\"UTD.htm?10/31/10743\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Mediastinal masses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"     \"Approach to chronic cough in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain chest radiographs demonstrate mediastinal masses in most cases. However, bronchogenic cysts may not be apparent on chest radiographs or may result in localized hyperinflation that resembles congenital lobar emphysema. Computed tomography, magnetic resonance imaging, ultrasound,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, and bronchoscopy all may play a role in the evaluation of mediastinal masses; the relative value of these studies depends upon the suspected underlying diagnosis, and is discussed separately (",
"    <a class=\"graphic graphic_table graphicRef73333 \" href=\"UTD.htm?33/53/34652\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Mediastinal masses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Functional causes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Aspiration syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration syndromes are important and often unrecognized causes of recurrent wheezing in young children. In many cases, these patients are misdiagnosed with difficult-to-control asthma. Aspiration syndromes are associated with a variety of anatomic and functional disorders. These disorders can be divided into four general categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foreign body aspiration typically presents with the abrupt onset of wheezing. However, patients may present with chronic cough, wheezing, or postobstructive pneumonia if the diagnosis is not recognized initially and the foreign body is retained (",
"      <a class=\"graphic graphic_algorithm graphicRef68288 \" href=\"UTD.htm?34/34/35374\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Foreign body aspiration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastroesophageal reflux (GER) seldom involves aspiration of large amounts of gastric contents. However, chronic microaspiration can cause significant mucosal edema and inflammation, and may result in chronic cough and wheezing. Infants who take a bottle to bed are at increased risk of both wheezing and asthma during the first five years of life, probably because of recurrent microaspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/18\">",
"       18",
"      </a>",
"      ]. Children with GER do not always report symptoms of reflux such as heartburn or vomiting but may present with more subtle findings, including nocturnal symptoms, hoarseness, or recurrent croup. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Swallowing disorders related to neurologic or muscular dysfunction of the pharynx",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      larynx can result in weakness and impaired swallowing, incomplete closure of the glottis, depressed cough reflex, and recurrent episodes of aspiration. Anatomic abnormalities, such as laryngeal clefts and vocal cord paralysis, can also cause swallowing dysfunction leading to aspiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=see_link\">",
"       \"Sucking and swallowing disorders in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=see_link\">",
"       \"Aspiration due to swallowing dysfunction in infants and children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The first step in making the diagnosis is to observe the child during feeding for difficulty with sucking or swallowing, fatigue, loss of interest, tachypnea, or apnea. The classic finding of coughing with feeding may be absent because of depression of the cough reflex caused by repeated stimulation of the receptors in the larynx and trachea.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       Barium",
"      </a>",
"      swallow under fluoroscopy using barium mixtures of different consistencies (also called a videofluoroscopic swallowing study), in conjunction with evaluation of swallowing by a speech-language pathologist, can be helpful for both diagnostic and therapeutic purposes.",
"     </li>",
"     <li>",
"      Fistulas between the tracheobronchial tree and other anatomical structures can cause wheezing. Tracheoesophageal fistulae, including laryngotracheobronchial clefts, are the most common of these conditions. Some infants with rare H-type fistulas are not diagnosed in the immediate postnatal period. These infants can present with chronic cough and recurrent pneumonia as well as wheezing. Symptoms such as coughing and choking are increased with feeding. Chest radiographs may show chronic or recurrent infiltrates, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      studies may be diagnostic. However, bronchoscopy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      esophagoscopy usually are needed to confirm this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"       \"Approach to chronic cough in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Host defense abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent infections of the lower respiratory tract can present with intermittent episodes of wheezing. These conditions can result in bronchiectasis, permanent tissue destruction, and chronic pulmonary disease if unrecognized or inadequately treated. Immune deficiency syndromes, especially those involving IgG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgA deficiency, are among the most common abnormalities that can cause recurrent bacterial respiratory infections. Both the upper and the lower respiratory tract can be involved and may result in recurrent otitis, pharyngitis, or pneumonia. Complement deficiency, T cell abnormalities, and defects in leukocyte phagocytic and chemotactic activity can result in recurrent upper and lower respiratory tract infection, but are less common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37978?source=see_link\">",
"     \"Pulmonary complications of primary immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary ciliary dyskinesia is a rare disease that can present with chronic cough and wheezing in children. This diagnosis should be considered in patients who present with recurrent severe upper respiratory infections, suppurative otitis (draining ears), and chronic sinusitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=see_link\">",
"     \"Primary ciliary dyskinesia (immotile-cilia syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) is the most common autosomal recessive disease among Caucasian populations, with a frequency of 1 in 2000 to 3000 live births. The usual presenting symptoms and signs include persistent pulmonary infection, pancreatic insufficiency, and elevated sweat chloride levels. However, many patients demonstrate mild or atypical symptoms, including wheezing, and clinicians should remain alert to the possibility of CF even when only a few of the usual features are present (",
"    <a class=\"graphic graphic_table graphicRef76253 \" href=\"UTD.htm?5/7/5244\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H8#H8\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Respiratory tract involvement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of CF is based upon compatible clinical findings with biochemical or genetic confirmation. The sweat chloride test should be performed to exclude cystic fibrosis in children with respiratory complaints in association with diarrhea, edema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure to thrive. There should be a low threshold to perform this test, since identifying a patient with cystic fibrosis has major implications for the patient, the family, and future reproductive decisions. Many states have implemented newborn screening for CF, but a negative newborn screen does not rule out CF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to wheezing in children\", section on 'Sweat chloride test'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bronchopulmonary dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopulmonary dysplasia (BPD), also known as neonatal chronic lung disease or chronic lung disease of infancy, is an important cause of respiratory illness in preterm newborns, particularly those with a birth weight less than 1250 g. The etiology of BPD is multifactorial. Most patients have a history of neonatal respiratory distress syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination is variable. Infants are often tachypneic. They may have mild to severe retractions, depending upon the extent of pulmonary edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atelectasis, and scattered rales may be audible. Intermittent expiratory wheezing can be present in infants with increased airway reactivity. Exacerbation of wheezing may occur in the setting of viral infection, physical exertion, GER, or fluid overload. Tracheomalacia and bronchomalacia are common bronchoscopic findings in children with BPD.",
"   </p>",
"   <p>",
"    The diagnosis of BPD primarily is based upon a history of prematurity and a supplemental oxygen requirement beyond 36 weeks gestational age. Chest radiographs may be diffusely hazy, reflecting inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary edema. Lung volumes are normal or low, and there may be areas of atelectasis that alternate with areas of gas trapping. Hyperinflation on chest radiograph suggests an airway component",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emphysematous changes. Streaky densities or cystic areas may be prominent and correspond to areas of fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Paradoxical vocal cord motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a condition that is seen in older children, usually teenagers, and adults. In the normal larynx, the true vocal cords abduct on inspiration and expiration and adduct during phonation, swallowing, coughing, or Valsalva maneuver. In contrast, paradoxical vocal cord motion (PVCM), or vocal cord dysfunction, is an inappropriate adduction of the true vocal cords on inspiration with abduction on expiration. The functional airway obstruction that arises from vocal cord adduction during inspiration results in significant respiratory distress and marked inspiratory stridor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PVCM is associated with a variety of psychosocial disorders; however, it is not considered to be a form of malingering as patients do not intentionally produce their condition for secondary gain. It is also associated with stress, exercise, perioperative airway and neurologic injury, gastroesophageal reflux, and irritant inhalational exposures. PVCM can be associated with underlying asthma, although more often it is misdiagnosed as asthma. In these patients, the incorrect diagnosis had led to excessive use of medications, including systemic glucocorticoids, repeated emergency department visits, frequent hospitalizations, intubation, and even tracheotomy.",
"   </p>",
"   <p>",
"    The clinical presentation can range from signs mimicking asthma or croup to total upper airway occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/19\">",
"     19",
"    </a>",
"    ]. The stridor resolves completely when the patient is asleep or immediately after endotracheal intubation or tracheotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients may complain of dyspnea, throat tightness, a choking sensation, dysphonia, and cough.",
"   </p>",
"   <p>",
"    Pulmonary function tests often are normal, although flow-volume loops on spirometry may show flattening of the inspiratory loop (",
"    <a class=\"graphic graphic_figure graphicRef63544 \" href=\"UTD.htm?40/55/41853\">",
"     figure 2",
"    </a>",
"    ), consistent with extrathoracic upper airway obstruction. Oxygen saturation by pulse oximetry is usually greater than 94 percent, even during episodes of significant respiratory distress. Visualization of the vocal cords when the patient is symptomatic using a flexible fiberoptic laryngoscope can confirm the diagnosis by revealing &lsquo;paradoxical&rsquo; adduction of the cords during inspiration and sometimes throughout the respiratory cycle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bronchiolitis obliterans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiolitis obliterans (BO) is a rare disease caused by epithelial injury to the lower respiratory tract that results in obstruction and obliteration of the distal airways [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/21\">",
"     21",
"    </a>",
"    ]. BO may occur after chemical, infectious, or immunologic injury, but can be idiopathic. Postviral bronchiolar damage is the most common cause of BO in the nontransplant population. Adenovirus is the most likely virus to cause BO, but other pathogens including influenza, measles, and mycoplasma have also been identified in association with BO [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/22\">",
"     22",
"    </a>",
"    ]. BO is a prominent manifestation of chronic lung transplant rejection and can occur in children following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. It is seen in children who have undergone hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37978?source=see_link&amp;anchor=H1322646#H1322646\">",
"     \"Pulmonary complications of primary immunodeficiencies\", section on 'Bronchiolitis obliterans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with BO usually present with tachypnea, dyspnea, persistent cough, and wheezing that is unresponsive to bronchodilator therapy. Hypoxemia is present in more severe cases, either at rest or only with exercise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    during sleep. Physical examination commonly reveals diffuse wheezing and crackles. Serial pulmonary function testing reveals airway obstruction without a substantial response to bronchodilators.",
"   </p>",
"   <p>",
"    Initially, the chest radiograph may appear normal or demonstrate hyperinflation or other nonspecific findings. Diffuse interstitial infiltrates, atelectasis, and bronchiectasis may be seen in advanced disease. High-resolution chest CT (HRCT) has become a useful tool in the diagnosis of BO, and may obviate the need for a lung biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. A mosaic pattern of hypolucency (due to air trapping) is seen, but may be missed without expiratory views that accentuate air trapping. The definitive diagnosis of BO requires a lung biopsy, although this is rarely done outside of the transplant populations.",
"   </p>",
"   <p>",
"    Several antiinflammatory strategies have been used for treatment of BO, with variable success. Management depends on the cause of the BO, as BO associated with bone marrow and lung transplants differs in progression and prognosis from BO due to postviral pneumonitis. Lung transplantation is an option for children who have severe and progressive disease and no response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1689/abstract/21,28,29\">",
"     21,28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the infant and child with interstitial lung disease\", section on 'Pharmacologic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the infant and child with interstitial lung disease\", section on 'Lung transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease (ILD), also known as interstitial pneumonitis, is a group of rare disorders that involve the lung parenchyma and interfere with gas exchange (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 5",
"    </a>",
"    ). Affected children usually present with progressive dyspnea and tachypnea with exercise intolerance, and less often with cyanosis. Wheezing is reported in about half of children with ILD, although it is found less frequently than that on physical examination. The presence of crackles, primarily inspiratory, is common in most forms of ILD. Digital clubbing is a late manifestation that suggests advanced fibrosis of the lungs. Pulmonary function testing typically shows a restrictive pattern, with reduced gas diffusion (DLCO). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2319105\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A wide variety of congenital and acquired conditions can cause narrowing of the extrathoracic or intrathoracic airways, and may present with wheezing (",
"      <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to asthma, acute onset of wheezing in a child is most often caused by infection or foreign body aspiration. The patient with a respiratory tract infection typically presents with a history of runny nose, cough, and fever. Foreign body aspiration (FBA) should be suspected in any patient who presents with sudden onset of cough and wheezing, especially if it is unilateral. A history of choking is highly suggestive of FBA, but it is not witnessed or recalled in all cases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Foreign body aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excluding asthma, the differential diagnosis of chronic or episodic wheezing is broad and includes structural abnormalities of the tracheobronchial tree or other thoracic structures (eg, vascular rings and slings, mediastinal masses). Nonstructural (functional) causes include aspiration syndromes (from gastroesophageal reflux and dysphagia), bronchopulmonary dysplasia, vocal cord dysfunction (including paradoxical vocal cord movement in older children), abnormal immunologic defense mechanisms, bronchiolitis obliterans, and interstitial lung disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Structural causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Functional causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localized or monophonic wheezing, croup-like cough or stridor, recurrent pneumonias, feeding difficulties, and lack of response to bronchodilator therapy all suggest a cause of wheezing other than asthma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute wheezing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Chronic or recurrent wheezing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/1\">",
"      Eldeirawi K, Persky VW. History of ear infections and prevalence of asthma in a national sample of children aged 2 to 11 years: the Third National Health and Nutrition Examination Survey, 1988 to 1994. Chest 2004; 125:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/2\">",
"      Patel SP, J&auml;rvelin MR, Little MP. Systematic review of worldwide variations of the prevalence of wheezing symptoms in children. Environ Health 2008; 7:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/3\">",
"      Taussig LM, Wright AL, Holberg CJ, et al. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol 2003; 111:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/4\">",
"      Bloomberg GR. Recurrent wheezing illness in preschool-aged children: assessment and management in primary care practice. Postgrad Med 2009; 121:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/5\">",
"      Finder JD. Understanding airway disease in infants. Curr Probl Pediatr 1999; 29:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/6\">",
"      McLaren CA, Elliott MJ, Roebuck DJ. Vascular compression of the airway in children. Paediatr Respir Rev 2008; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/7\">",
"      Moss AJ, McDonald LV. Cardiac disease in the wheezing child. Chest 1977; 71:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/8\">",
"      Rabinovitch M, Grady S, David I, et al. Compression of intrapulmonary bronchi by abnormally branching pulmonary arteries associated with absent pulmonary valves. Am J Cardiol 1982; 50:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/9\">",
"      Lee SL, Cheung YF, Leung MP, et al. Airway obstruction in children with congenital heart disease: assessment by flexible bronchoscopy. Pediatr Pulmonol 2002; 34:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/10\">",
"      Martinati LC, Boner AL. Clinical diagnosis of wheezing in early childhood. Allergy 1995; 50:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/11\">",
"      Tsubata S, Ichida F, Miyazaki A, et al. Bronchial hyper-responsiveness to inhaled histamine in children with congenital heart disease. Acta Paediatr Jpn 1995; 37:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/12\">",
"      Pisanti A, Vitiello R. Wheezing as the sole clinical manifestation of cor triatriatum. Pediatr Pulmonol 2000; 30:346.",
"     </a>",
"    </li>",
"    <li>",
"     Reisman JJ, Canny GJ, Levison H. Wheezing in infants and young children. In: Childhood asthma-pathophysiology and treatment, 2nd ed, Tinkelman DG, Naspitz CK (Eds), Marcel Dekker, New York 1993. p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/14\">",
"      Ferreira SM, Ferreira AG Jr, Meguins LC, Neto DB. Asthma as a clinical presentation of cor triatriatum sinister in a Brazilian Amazon child: a case report. J Cardiovasc Med (Hagerstown) 2009; 10:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/15\">",
"      Turner A, Gavel G, Coutts J. Vascular rings--presentation, investigation and outcome. Eur J Pediatr 2005; 164:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/16\">",
"      Bakker DA, Berger RM, Witsenburg M, Bogers AJ. Vascular rings: a rare cause of common respiratory symptoms. Acta Paediatr 1999; 88:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/17\">",
"      Ruzmetov M, Vijay P, Rodefeld MD, et al. Follow-up of surgical correction of aortic arch anomalies causing tracheoesophageal compression: a 38-year single institution experience. J Pediatr Surg 2009; 44:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/18\">",
"      Celed&oacute;n JC, Litonjua AA, Ryan L, et al. Bottle feeding in the bed or crib before sleep time and wheezing in early childhood. Pediatrics 2002; 110:e77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/19\">",
"      Maturo S, Hill C, Bunting G, et al. Pediatric paradoxical vocal-fold motion: presentation and natural history. Pediatrics 2011; 128:e1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/20\">",
"      Patterson R, Schatz M, Horton M. Munchausen's stridor: non-organic laryngeal obstruction. Clin Allergy 1974; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/21\">",
"      Moonnumakal SP, Fan LL. Bronchiolitis obliterans in children. Curr Opin Pediatr 2008; 20:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/22\">",
"      Fischer GB, Sarria EE, Mattiello R, et al. Post infectious bronchiolitis obliterans in children. Paediatr Respir Rev 2010; 11:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/23\">",
"      Park M, Koh KN, Kim BE, et al. Clinical features of late onset non-infectious pulmonary complications following pediatric allogeneic hematopoietic stem cell transplantation. Clin Transplant 2011; 25:E168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/24\">",
"      Nishio N, Yagasaki H, Takahashi Y, et al. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children. Bone Marrow Transplant 2009; 44:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/25\">",
"      Sweet SC. Pediatric lung transplantation. Proc Am Thorac Soc 2009; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/26\">",
"      Colom AJ, Teper AM. Clinical prediction rule to diagnose post-infectious bronchiolitis obliterans in children. Pediatr Pulmonol 2009; 44:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/27\">",
"      Gunn ML, Godwin JD, Kanne JP, et al. High-resolution CT findings of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. J Thorac Imaging 2008; 23:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/28\">",
"      Yamane M, Sano Y, Toyooka S, et al. Living-donor lobar lung transplantation for pulmonary complications after hematopoietic stem cell transplantation. Transplantation 2008; 86:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1689/abstract/29\">",
"      M&uuml;ller C, G&ouml;rler H, Ballmann M, et al. Pulmonary retransplantation in paediatric patients: a justified therapeutic option? A single-centre experience. Eur J Cardiothorac Surg 2011; 39:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5751 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1689=[""].join("\n");
var outline_f1_41_1689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2319105\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE WHEEZING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Foreign body aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHRONIC OR RECURRENT WHEEZING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Structural causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Anomalies of the tracheobronchial tree",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7432047\">",
"      - Mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Functional causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Aspiration syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Host defense abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2319105\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5751\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5751|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/34/35374\" title=\"algorithm 1\">",
"      Natural hx FBA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5751|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/37/29279\" title=\"diagnostic image 1A\">",
"      Obstructive emphysema A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/43/32447\" title=\"diagnostic image 1B\">",
"      Obstructive emphysema B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5751|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/31/10743\" title=\"figure 1\">",
"      Mediastinal mass compartment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/55/41853\" title=\"figure 2\">",
"      Flow volume loop airway lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5751|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/40/24204\" title=\"table 1\">",
"      Causes of wheeze in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/25/11675\" title=\"table 2\">",
"      Chest radiograph findings in vascular rings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/53/34652\" title=\"table 3\">",
"      Radiography mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/7/5244\" title=\"table 4\">",
"      Symptoms of cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/32/31245\" title=\"table 5\">",
"      Classification pediatric ILD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=related_link\">",
"      Apparent life-threatening event in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=related_link\">",
"      Approach to chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=related_link\">",
"      Approach to the infant and child with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=related_link\">",
"      Aspiration due to swallowing dysfunction in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=related_link\">",
"      Bacterial tracheitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=related_link\">",
"      Bronchiolitis in infants and children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=related_link\">",
"      Pathophysiology of left to right shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=related_link\">",
"      Primary ciliary dyskinesia (immotile-cilia syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37978?source=related_link\">",
"      Pulmonary complications of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29385?source=related_link\">",
"      Pulmonary veno-occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=related_link\">",
"      Virus-induced wheezing and asthma: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_41_1690="Approach to the adult with epistaxis";
var content_f1_41_1690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult with epistaxis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/41/1690/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/41/1690/contributors\">",
"     Harrison Alter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/41/1690/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/41/1690/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/41/1690/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/41/1690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/41/1690/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/41/1690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epistaxis is a common problem, occurring in up to 60 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/1\">",
"     1",
"    </a>",
"    ]. While most episodes are uncomplicated, epistaxis can occasionally be difficult to control. Knowledge of the basic anatomy of the nasopharynx and a few hemostatic strategies are reassuring in the face of acute hemorrhage.",
"   </p>",
"   <p>",
"    This topic addresses epistaxis in adults. Epistaxis in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=see_link\">",
"     \"Management of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survey data suggest that although 60 percent of adults have experienced an epistaxis episode, only 10 percent have required medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/2\">",
"     2",
"    </a>",
"    ]. Epistaxis is a common otolaryngologic cause for hospital admission, although surgical intervention is rarely needed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epistaxis appears to have a bimodal age distribution, with most cases occurring before age 10 or between 45 and 65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/1\">",
"     1",
"    </a>",
"    ]. Hospital admission for epistaxis increases progressively with age, but these data do not control for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or anticoagulant use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/4\">",
"     4",
"    </a>",
"    ]. Among hospitalized patients, there is male predominance prior to age 49, after which the sex distribution equalizes. This phenomenon has been attributed to a protective effect of estrogen in women, whether in fostering a healthy nasal mucosa or in preventing vascular disease more generally [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seasonal variation, with predominance in winter months, has been found in most [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/6-10\">",
"     6-10",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/11\">",
"     11",
"    </a>",
"    ], studies. Seasonal factors affecting epistaxis include the incidence of upper respiratory infections, allergic rhinitis, and mucosal changes associated with fluctuations in temperature and humidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epistaxis may be classified as anterior or posterior, depending upon the source of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anterior bleeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior nosebleeds are by far the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/12\">",
"     12",
"    </a>",
"    ]. A large proportion is self-limited and can be managed definitively in the primary care setting.",
"   </p>",
"   <p>",
"    Up to 90 percent occur within the vascular watershed area of the nasal septum known as Kiesselbach's plexus (",
"    <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/13\">",
"     13",
"    </a>",
"    ]. Anastomosis of three primary vessels occurs in this area: the septal branch of the anterior ethmoidal artery; the lateral nasal branch of the sphenopalatine artery; and the septal branch of the superior labial branch of the facial artery. The sphenopalatine artery also gives off branches supplying the posterolateral wall and posterior choana; these vessels are the most likely source of posterior nosebleeds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Posterior bleeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior epistaxis arises most commonly from the posterolateral branches of the sphenopalatine artery but may also arise from the carotid artery (",
"    <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Posterior nosebleeds can result in significant hemorrhage. The skilled clinician may temporize with nasal packing, but most patients require prompt referral to an emergency department, possible consultation with an otolaryngologist, and sometimes hospital admission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior nosebleeds often result from mucosal trauma or irritation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nose picking is a common cause. The source is usually just proximal to the mucocutaneous junction where there is little subcutaneous tissue into which an excoriated vessel can retract.",
"     </li>",
"     <li>",
"      Low moisture content in the ambient air can result in mucosal dryness and irritation. This factor is common in centrally-heated rooms that are not humidified.",
"     </li>",
"     <li>",
"      The mucosal hyperemia that accompanies allergic or viral rhinitis makes bleeding from local trauma especially profuse, which may prompt patients to seek medical care.",
"     </li>",
"     <li>",
"      The presence of a foreign body should be considered when bleeding is accompanied by purulent discharge; sinusitis is also in the differential diagnosis in these circumstances.",
"     </li>",
"     <li>",
"      Chronic excoriation can lead to small septal perforations that may bleed from surrounding friable granulation tissue; chronic intranasal drug use (eg, cocaine) may present similarly.",
"     </li>",
"     <li>",
"      Patients who suffer facial trauma from a motor vehicle crash or other blunt facial impact often bleed from the nose, usually from an anterior source.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anterior and posterior bleeds may be caused by a number of associated conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulated patients are at high risk for nosebleeds. The role of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      cessation and reversal of anticoagulation are controversial in the setting of epistaxis. Patients who are in the therapeutic INR range for their specific indication and in whom hemostasis is achieved may be safely maintained on their warfarin regimen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"       \"Correcting excess anticoagulation after warfarin\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      One large retrospective study in an anticoagulation clinic noted that reversal was required for epistaxis at a rate of only 1.5 per 1000 patient-years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/14\">",
"       14",
"      </a>",
"      ], despite patient recall data in the same hospital suggesting an annual incidence of epistaxis of 25 percent among anticoagulated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epistaxis is the most common presenting symptom among patients with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/16\">",
"       16",
"      </a>",
"      ]. The bleeding can be quite difficult to control in these individuals. The friable lesions may appear to bleed more with treatment than without. Nevertheless, the treating clinician should initiate hemostatic measures and obtain appropriate consultation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"       \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with familial blood dyscrasias, particularly platelet disorders, von Willebrand disease, and hemophilia, are prone to epistaxis. A bleeding diathesis should be considered in the patient with recurrent spontaneous epistaxis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"       \"Approach to the adult patient with a bleeding diathesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent posterior bleeds or massive hemorrhage may be due to aneurysm of the carotid artery [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/19\">",
"       19",
"      </a>",
"      ]. This is of particular concern in a patient with a prior history of head and neck surgery, or following trauma (pseudoaneurysm) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/20\">",
"       20",
"      </a>",
"      ], but most often posterior bleeds arise spontaneously.",
"     </li>",
"     <li>",
"      Epistaxis may be a symptom of a nasal neoplasm. The most common tumors associated with epistaxis are squamous cell carcinoma, adenoid cystic carcinoma, melanoma, and inverted papilloma [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/13\">",
"       13",
"      </a>",
"      ]. Nasopharyngeal cancers are more common in patients of Chinese or southeast Asian heritage. Patients who have had significant epistaxis (posterior bleed) should receive a thorough ENT evaluation after the bleeding has been controlled.",
"     </li>",
"     <li>",
"      The data on the importance of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      as a risk factor for epistaxis are not definitive [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/21\">",
"       21",
"      </a>",
"      ]. In one study of habitual nose bleeders, the recalled rate of aspirin use did not differ from that of controls [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/22\">",
"       22",
"      </a>",
"      ]. In contrast, another case control study found a positive correlation between aspirin use and epistaxis (RR 2.17 or 2.75, depending upon whether a community or hospital control group was used) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/23\">",
"       23",
"      </a>",
"      ]. There is no reported increase in risk associated with other nonsteroidal antiinflammatory drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The association between hypertension and epistaxis is uncertain. Multiple studies have related hypertension to nosebleeds [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/3,7,24-26\">",
"       3,7,24-26",
"      </a>",
"      ], although studies specifically exploring this relationship have been unable to confirm the association [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/5,15,27-29\">",
"       5,15,27-29",
"      </a>",
"      ]. Some data suggest that longstanding hypertension may contribute to an elevated risk of epistaxis, most likely due to its vasculopathic effects [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/28\">",
"       28",
"      </a>",
"      ]. Some specialists suggest that hypertension does not cause epistaxis, but does prolong episodes of bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alcohol may increase the risk for epistaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/31\">",
"       31",
"      </a>",
"      ], as may intranasal preparations for seasonal allergies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/32\">",
"       32",
"      </a>",
"      ]. Nasal steroids are used with increasing frequency, and their contribution to the incidence of anterior nosebleeds is likely to increase. A placebo study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      nose drops found a significant increase in epistaxis in the treatment group (19 percent compared with 4 percent for placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of epistaxis should focus on airway assessment and cardiovascular stability. Airway intervention, fluid resuscitation, and emergent otolaryngologic consultation can be necessary in severe epistaxis. Normal appearance, vital signs, and respiratory function are evidence that the examiner can safely attend to the presenting complaint. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should address the following issues [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conditions that predispose to bleeding, possibly including tumors, coagulation disorders (personal and family history), recent trauma or surgery, medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , intranasal glucocorticoids), and other conditions (eg, cirrhosis, HIV, intranasal cocaine use).",
"     </li>",
"     <li>",
"      The timing, frequency, and severity of epistaxis should be assessed (eg, is this an isolated episode or one of many?).",
"     </li>",
"     <li>",
"      The possible presence of chronic medical problems that can be exacerbated by blood loss, such as coronary artery disease and chronic obstructive pulmonary disease, and symptoms that may be related (eg, chest discomfort, dyspnea, lightheadedness).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Coagulation studies and other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prothrombin time (PT) with international normalized ratio (INR) is",
"    <strong>",
"     NOT",
"    </strong>",
"    indicated as a routine test, but should be ordered for the anticoagulated patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A hematocrit and type and crossmatch should be obtained in the setting of massive or prolonged hemorrhage, and two large bore IV lines placed in such cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Properly instructed patients may achieve hemostasis unassisted while the evaluation gets underway. The following approach may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient blows their nose to remove blood and clots",
"     </li>",
"     <li>",
"      Clinician sprays the nares with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"     </li>",
"     <li>",
"      Patient pinches the alae tightly against the septum and holds continuously for ten minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many otolaryngologists recommend initial treatment with two sprays of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    (Afrin) to hasten hemostasis, although little published data exist to support the practice. One small retrospective study found that oxymetazoline spray stopped bleeding in 65 percent of patients presenting to an emergency department with epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/37\">",
"     37",
"    </a>",
"    ]. The application of oxymetazoline for the purpose of reducing bleeding through vasoconstriction is unlikely to cause an elevation in blood pressure.",
"   </p>",
"   <p>",
"    To achieve tamponade, the patient must exert pressure properly by grasping the alae distally and pinching them tightly against the septum such that the mucosal surfaces are tightly apposed (",
"    <a class=\"graphic graphic_picture graphicRef66257 \" href=\"UTD.htm?32/47/33535\">",
"     picture 1",
"    </a>",
"    ). The patient should maintain this position continuously for ten to fifteen minutes without releasing pressure to see if the bleeding has stopped.",
"   </p>",
"   <p>",
"    Other maneuvers include having the patient bend forward at the waist while sitting up (to avoid swallowing blood), placing a plug of cotton wool or a pledget into the bleeding nostril (sometimes coated with antibiotic ointment), expectorating blood that accumulates in the pharynx, and applying a cold compress to the bridge of the nose. These maneuvers should be taught to patients for use at home [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/15\">",
"     15",
"    </a>",
"    ]. The anxious patient may be given a small parenteral dose of an anxiolytic medication, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Another initial measure commonly practiced by otolaryngologists is the acute reduction of elevated blood pressures in the setting of epistaxis, with the idea that bleeding will not be controlled while systemic pressures remain high [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/38\">",
"     38",
"    </a>",
"    ]. This practice has not been studied in prospective trials and its validity remains unclear. Furthermore, some patients do not tolerate acute reductions in blood pressure. For these reasons, we believe that, in the absence of a hypertensive emergency, antihypertensive medications should",
"    <strong>",
"     NOT",
"    </strong>",
"    be part of initial therapy for epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to assess the vital signs, mental status, and airway of any patient with significant bleeding, looking for signs of airway compromise or hypovolemic shock. This assessment is particularly important in the elderly and those with severe systemic disease. In patients with recurrent nosebleeds, the patient should be evaluated for signs of coagulopathy (eg, ecchymoses, petechiae, telangiectatic lesions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pretreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasal cavity should be anesthetized prior to performing a detailed examination, which otherwise is uncomfortable. Adequate anesthesia can often be achieved with cotton swabs soaked in an anesthetic and vasoconstrictive agent. Drugs commonly used for this purpose include 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , lidocaine with epinephrine, and 4 percent cocaine. These agents have not been studied in primary epistaxis, but a small literature on the prevention of epistaxis in nasotracheal intubation suggests that they are roughly equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selected medication may be applied using two saturated cotton swabs, one placed directly posteriorly and another posterosuperiorly, or with saturated cotton pledgets hand rolled from cotton wool and placed in the nose with bayonet forceps.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"     Oxymetazoline",
"    </a>",
"    nasal preparation, although it has no anesthetic properties, can provide vasoconstriction. It is administered as two sprays. Oxymetazoline is readily available, convenient, and inexpensive. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    is NOT recommended following reports of several deaths associated with its use intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Examination of the nose",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to obtain as clear and complete a view of the nares as possible. Ideally, the patient should be examined in a dental chair or its equivalent. If this is unavailable, bring the head of an examination table to upright so the patient can sit comfortably while head movement is restricted. Good lighting is essential, preferably with a headlamp or mirror. Use an emesis basin to catch blood and expectorated clots. Encourage the patient to spit posterior pharyngeal blood into the basin as this will reduce the risk of emesis and aspiration.",
"   </p>",
"   <p>",
"    An adequate examination for the source of bleeding requires use of a nasal speculum; an otoscope speculum is significantly less effective [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/34,42\">",
"     34,42",
"    </a>",
"    ]. When inserted, the nasal speculum is oriented so one blade moves superiorly and the other moves inferiorly.",
"   </p>",
"   <p>",
"    Further techniques to optimize use of the nasal speculum are based upon anecdote. The clinician can stabilize the speculum's position by placing his or her index finger on the bridge of the patient's nose. Alternatively, the clinician can use the index finger to press the nasal alae against the superior blade of the speculum, once it is inserted. This allows only the lower blade to move and may reduce patient discomfort.",
"   </p>",
"   <p>",
"    Ask the patient to look directly ahead and attempt the sniffing position. Patients often try to tilt the head back to facilitate a nasal examination, but the nasopharynx lies in the anteroposterior plane and extension of the neck will obscure most of the cavity from view [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clots may be cleared either with suction or by asking the patient to gently blow his or her nose. The most common suction setup, the Yankauer tip, is poorly suited to the nares, and the surgeon's Zoellner sucker is often too small. Some clinicians have found a disposable tube connector or a Frazier suction catheter to be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inspect the area of Kiesselbach's plexus first since the majority of bleeds originate here (",
"    <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"     figure 1",
"    </a>",
"    ). Look closely for bleeding, ulceration, or erosion. It is sometimes helpful to displace coagulum gently with a cotton swab to identify a bleeding source. Also inspect the nasal vestibule, septum, and turbinates for sources of bleeding.",
"   </p>",
"   <p>",
"    Not uncommonly, a primary bleeding site cannot be identified. In such cases, bleeding may stem from a posterior source, including a mass that is difficult to identify, or a trivial insult to the nasal mucosa that has resolved spontaneously or following noninvasive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Distinguishing anterior and posterior bleeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can sometimes be difficult to determine the source of epistaxis. Neither the volume nor the rate of bleeding is helpful; anterior bleeding can be brisk. However, minor bleeding is unlikely to originate posteriorly. While pinching the alae stops many but not all anterior bleeds, many posterior bleeds stop spontaneously making interpretation difficult. Perhaps the best way to determine the bleeding source in difficult cases is to place bilateral anterior nasal packing and examine the patient. Brisk bleeding despite proper packing strongly suggests a posterior source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT OF ANTERIOR BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sometimes minor anterior nosebleeds resolve without intervention prior to clinical evaluation or with the initial attempt at tamponade described above. If no anterior source is evident and bleeding has stopped, the nose should be packed only if bleeding recurs rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/34\">",
"     34",
"    </a>",
"    ]. It is reasonable to observe the patient for approximately 30 minutes for recurrent bleeding. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Initial tamponade'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The attached flowchart presents a general approach to adult patients with epistaxis (",
"    <a class=\"graphic graphic_algorithm graphicRef82548 \" href=\"UTD.htm?29/15/29951\">",
"     algorithm 1",
"    </a>",
"    ). A list of the equipment that may be needed for epistaxis management is provided (",
"    <a class=\"graphic graphic_table graphicRef58901 \" href=\"UTD.htm?40/3/41019\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cautery",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an anterior bleeding source is visualized, first-line treatment consists of chemical or electrical cautery. Chemical cautery is usually performed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    sticks, which are used in the following manner. After determining that topical anesthesia is adequate, apply the applicator tip to a small area surrounding the bleeding site. Begin at the periphery of this small area and move towards the center, starting proximally. Avoid cauterizing large areas and remove excess silver nitrate with a cotton swab [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/34,42\">",
"     34,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cautery is applied for a few seconds (no longer than 10 seconds), until a white precipitate forms. Both types of cautery may cause rhinorrhea and crusting. Avoid overzealous cautery of the septum, which can lead to ulceration and perforation. Rarely, if ever, should both sides of the septum be cauterized in the same session in order to avoid tissue necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    requires moisture to act, it will work only on a relatively bloodless surface; the bleeding point itself cannot be cauterized until hemostasis is achieved either through proximal cautery, vasoconstrictive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    drops, or tamponade from manual pressure. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Initial tamponade'",
"    </a>",
"    above.) Suction may be used to dry areas with minor bleeding. Electrical cautery works equally well [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/44\">",
"     44",
"    </a>",
"    ], but is also not effective on bloody surfaces. Cautery can be extremely painful if the patient is inadequately anesthetized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nasal packing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If cautery is unsuccessful, the next step in the management of suspected anterior epistaxis is nasal packing to tamponade local bleeding. Several packing options are available (",
"    <a class=\"graphic graphic_picture graphicRef71487 \" href=\"UTD.htm?38/5/39006\">",
"     picture 2",
"    </a>",
"    ). Before nasal packing is placed, the anxious patient may be given a small parenteral dose of an anxiolytic medication, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Nasal tampons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal packing is most easily accomplished with a nasal tampon. These are usually made of Merocel&trade;, a synthetic open-cell foam polymer that appears to provide a less hospitable medium for Staphylococcus aureus (S. aureus) than traditional gauze packing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Antibiotics and toxic shock syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The Merocel&trade; tampon is easy to use and effective. It is inserted as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Position the patient properly and pretreat with a topical anesthetic (eg, 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ) and topical vasoconstrictor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      ). Proper patient positioning and pretreatment are discussed above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coat the tampon with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      ointment to facilitate placement, and possibly decrease the risk of toxic-shock syndrome.",
"     </li>",
"     <li>",
"      Insert the tampon by sliding it directly along the floor of the nasal cavity until nearly the entire tampon lies within the nasal cavity.",
"     </li>",
"     <li>",
"      Large nares can be packed with two tampons (be sure to leave the tips of both exposed for removal); small nares can be packed with a pediatric tampon or an adult tampon trimmed with an iris scissor.",
"     </li>",
"     <li>",
"      Expand the tampon by infusing approximately 10 mL of saline, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      solution if available. A 22-gauge angiocatheter on a saline-filled syringe can be used to expand the deep portion of the tampon first and to speed diffusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gauze packing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal packing can be achieved using ribbon gauze, which is dispensed in 180 cm (72 inch) lengths, though this approach requires greater skill. The gauze is impregnated with petrolatum (eg, Xeroform&trade;) or bismuth subnitrate and iodoform paste (BIPP). The procedure involves stacking layers of gauze in an accordion fashion, starting on the floor of the nasal cavity.",
"   </p>",
"   <p>",
"    To insert the packing, grasp the gauze with a bayonet forceps, leaving an approximately 10 cm (4 inch) tail [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/13\">",
"     13",
"    </a>",
"    ]. Next, gingerly advance the gauze as far as possible into the nasal cavity without touching the walls of the nasopharynx. Then grasp another 8 to 10 cm of gauze and advance it atop the prior layer. Repeat this process until the nose is tightly packed.",
"   </p>",
"   <p>",
"    One small randomized trial found no difference between the Merocel&trade; tampon and BIPP-impregnated gauze packing (similar to Xeroform&trade;) in controlling epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Nasal balloon catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, balloon catheters are easier to use than gauze packing, particularly for clinicians with little experience performing packing. However, the techniques are probably equally effective. Both procedures are uncomfortable and may require the use of parenteral opioids or anxiolytics.",
"   </p>",
"   <p>",
"    Several balloon-style products are available to tamponade anterior, and posterior, nosebleeds. The Epistat&trade; and Storz T-3100 balloons have a lumen that allows for oxygen delivery and both anterior and posterior balloons. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Treatment of posterior bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The Rapid Rhino&trade; is a balloon catheter with a large, low-pressure air balloon encased in a carboxymethylated cellulose (CMC) mesh, available in a 5 cm length for anterior bleeds and 7.5 cm for posterior epistaxis. The Rapid Rhino&trade; becomes slick when it is placed in water for 30 seconds, making placement easier. Upon contact with blood, the CMC fibers act to promote thrombosis.",
"   </p>",
"   <p>",
"    The Rapid Rhino&trade; is inserted as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Position the patient properly and pretreat with a topical anesthetic (eg, 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ) and topical vasoconstrictor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      ). Proper patient positioning and pretreatment are discussed above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Soak the catheter in sterile water for 30 seconds. Do NOT use saline and do NOT apply lubricants or topical antibiotics, which impair the CMC fibers.",
"     </li>",
"     <li>",
"      Insert the catheter by sliding it along the floor of the nasal cavity until the plastic proximal fabric ring lies within the nares.",
"     </li>",
"     <li>",
"      Inflate the catheter with air only using a 20 mL syringe; stop inflating when the pilot cuff is round and firm. The appropriate amount of air varies with the size of the nasal cavity.",
"     </li>",
"     <li>",
"      After 10 to 15 minutes, reassess the pilot cuff. Add air if it is no longer round and firm. Tape the pilot cuff to the patient's cheek.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of two small randomized trials and observational data suggest there is no difference between a nasal tampon and the Rapid Rhino&trade; balloon catheter in controlling epistaxis, but note that the Rapid Rhino&trade; appears to cause less discomfort and is easier to insert [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. No significant differences in rebleeding after removal of the devices were reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Thrombogenic foams and gels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gel and foam products that promote thrombogenesis are being developed and tested for treatment of epistaxis. Quixil&trade;, a fibrin glue, is safe, and probably as effective as cautery and packing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/51\">",
"     51",
"    </a>",
"    ]. Floseal&trade;, a bovine-derived thrombin gel, was associated with an absolute 26 percent lower rebleeding rate compared with nasal packing and was easier to insert and judged more satisfactory by both providers and patients in a randomized trial of 70 patients with acute anterior nosebleeds [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/52\">",
"     52",
"    </a>",
"    ]. In another prospective study, FloSeal&trade; effectively controlled posterior bleeds in 8 of 10 patients whose initial hemostatic packing failed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgicel&reg;, Gelfoam&reg;, and Avitene&reg;, all common conformable hemostatic materials, have each been described in reviews or small case series as useful in nasal bleeding refractory to cautery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/11,30\">",
"     11,30",
"    </a>",
"    ]. These materials can be trimmed to an appropriate size using an iris scissor and then applied directly to the bleeding source with a bayonet forceps. Once applied, the material should be held in place with firm pressure for approximately one minute to ensure adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Persistent bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;If bleeding persists despite the initial packing, the contralateral naris may be packed, thereby providing a counterforce to promote tamponade. Some clinicians obtain otolaryngologic consultation once bilateral packing is needed, although the risk of aspiration, hypoxic complications, and treatment failure is small in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/46,54\">",
"     46,54",
"    </a>",
"    ]. In most cases, 24 to 48 hour follow-up with the consultant is adequate.",
"   </p>",
"   <p>",
"    Nasal packing in anterior bleeding has about a 90 to 95 percent success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/46,54\">",
"     46,54",
"    </a>",
"    ]. If bilateral anterior packing fails to produce hemostasis, the odds of a posterior source increase greatly. Patients with posterior bleeds need posterior packing and probably hospitalization. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Treatment of posterior bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As mentioned above, patients with hereditary hemorrhagic telangiectasia can have severe recurrent epistaxis that is resistant to usual management measures. A report of one such case found that application of five drops (about 0.25 mL) of 100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (an antifibrinolytic agent) at the onset of bleeding reduced the need for blood transfusions and iron supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link&amp;anchor=H9#H9\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\", section on 'Epistaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antibiotics and toxic shock syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of toxic shock syndrome (TSS) following postoperative nasal packing is estimated at about 16 per 100,000 packings. Although the incidence in primary nasal packing has not been established, it is prudent for clinicians and patients to be alert for signs of toxic shock syndrome (fever, hypotension, desquamation, and mucosal hyperemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link\">",
"     \"Staphylococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic antibiotics appear to be of little use in reducing nasal carriage of Staphylococcus aureus (S. aureus) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/45,56,57\">",
"     45,56,57",
"    </a>",
"    ]. There are no studies that have directly examined the effect of systemic antibiotics on rates of TSS since it is such a rare event. In addition to the lack of proven efficacy of antibiotics, significant adverse outcomes might occur more commonly than TSS if antibiotics were given routinely. Such outcomes include allergic reactions and the development of bacterial strains with resistance to antibiotics.",
"   </p>",
"   <p>",
"    Use of antibiotics has also been suggested for prevention of secondary bacterial sinus infections, but again there are no studies to support this approach. One small prospective study of patients treated with anterior nasal packing for epistaxis found no evidence of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, despite the lack of proven efficacy, many ENT specialists prefer to provide prophylaxis against TSS and antibiotics are commonly prescribed in patients with nasal packing for the duration of the packing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/46,49,52,54,59-61\">",
"     46,49,52,54,59-61",
"    </a>",
"    ]. We prefer to avoid giving antibiotics and believe they should not be given routinely for prophylaxis against infection in patients with anterior nasal packing. The decision to prescribe antibiotics is appropriately individualized to the patient. It may be reasonable to treat patients at greater risk of infection, such as those with diabetes, advanced age, or immunosuppression.",
"   </p>",
"   <p>",
"    If prescribed, an antibiotic with staphylococcal coverage should be selected, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    or a second-generation cephalosporin; topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    may also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;If vital signs and respiratory function remain normal after packing, the patient may be safely referred for specialist follow-up in 24 to 48 hours, with advice to present to an emergency department sooner if bleeding recurs.",
"   </p>",
"   <p>",
"    Some clinicians opt for urgent otolaryngologic consultation once acute anterior epistaxis has progressed to the point of needing bilateral packing, although the risk of aspiration, hypoxic complications, and treatment failure is small in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/46,54\">",
"     46,54",
"    </a>",
"    ]. In most cases, 24 to 48 hour follow-up is adequate.",
"   </p>",
"   <p>",
"    After 24 to 48 hours, a more thorough examination may be possible, although tumors or other abnormalities that may have been missed in the acute setting are seldom found. Nasal packing, particularly Merocel&trade;, should be rehydrated with saline drops prior to removal for patient comfort.",
"   </p>",
"   <p>",
"    Specialty referral may not be necessary for healthy patients with stable vital signs and uncomplicated bleeding from a clearly identified source that resolves with simple cautery or one-time packing. Such patients should be reassessed when the packing is removed at 48 hours. Referral to an otolaryngologist is warranted in patients who do not meet ALL of these criteria, or about whom the clinician has questions or concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated anterior bleeds should be advised to sleep in a humidified environment. Although proof of efficacy is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/62\">",
"     62",
"    </a>",
"    ], a topical antibacterial (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ) or bacteriostatic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ) ointment may be gently applied to the nasal mucosa with a cotton-tipped swab in an attempt to prevent recurrence. Directing nasal medication sprays away from the septum may decrease the risk of epistaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREATMENT OF POSTERIOR BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute management of a posterior nosebleed differs from that of an anterior bleed, although it is also based upon the principle of tamponade. Of the several methods of posterior packing described, we prefer balloon catheters. If balloon catheters are not available, alternatives include a Foley catheter and cotton packing.",
"   </p>",
"   <p>",
"    A list of the equipment that may be needed for epistaxis management is provided (",
"    <a class=\"graphic graphic_table graphicRef58901 \" href=\"UTD.htm?40/3/41019\">",
"     table 1",
"    </a>",
"    ). Immediate otolaryngologic consultation is necessary if bleeding is heavy and cannot be controlled with posterior packing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Balloon catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloon catheters were developed to simplify posterior nasal packing. Examples include the Epistat&trade; and Storz T-3100. One model of the balloon catheter combines a small posterior balloon and a large anterior balloon. Such double balloon catheters are inserted as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Position the patient properly and pretreat with a topical anesthetic (eg, 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ) and topical vasoconstrictor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      ). Proper patient positioning and pretreatment are discussed above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advance the catheter along the floor of the nasal cavity until the retention ring reaches the entrance of the naris.",
"     </li>",
"     <li>",
"      Inflate the posterior balloon with 10 mL of sterile saline.",
"     </li>",
"     <li>",
"      Retract the catheter gently until it lodges against the posterior choana in the nasopharynx.",
"     </li>",
"     <li>",
"      Once the posterior balloon is seated, inflate the anterior balloon with 30 mL of sterile saline. If the patient experiences severe pain or deviation of the nasal septum or soft palate, gradually deflate the anterior balloon until the pain or deviation resolve.",
"     </li>",
"     <li>",
"      Pad and protect the alae and naris entrance as necessary to prevent excessive pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some balloon catheters are designed to be used with air. The Epistat&trade; II has a posterior balloon and an anterior Merocel&trade; nasal tampon. Some devices are built around a central air passage to facilitate nose breathing. All balloon catheters are designed for temporary control of bleeding and should NOT be left in place for more than three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Foley catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a balloon catheter is not available, posterior tamponade can be achieved by insertion of a 10 to 14 French Foley catheter using the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Position the patient properly and pretreat with a topical anesthetic (eg, 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ) and topical vasoconstrictor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      ). Proper patient positioning and pretreatment are discussed above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before insertion, coat the catheter with a suitable, petroleum-free lubricant and trim the tip of the catheter to minimize irritation of the posterior structures.",
"     </li>",
"     <li>",
"      Advance the catheter along the floor of the nose until it is visible in the posterior oropharynx.",
"     </li>",
"     <li>",
"      Partially fill the balloon with 5 to 7 mL of sterile saline.",
"     </li>",
"     <li>",
"      Retract the catheter gently until it lodges against the posterior choana in the nasopharynx.",
"     </li>",
"     <li>",
"      Complete the filling of the balloon by adding another 5 mL of sterile saline. Pain or distention of the soft palate suggests overfilling.",
"     </li>",
"     <li>",
"      Clamp the catheter in place with an umbilical clamp or small c-clamp, as from a nasogastric tube. Place padding between the clamp and the alae to prevent excessive pressure, which otherwise can lead to necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinicians prefer filling the balloon with air to minimize the risk of saline aspiration with balloon failure (which has never been reported). However, the use of air in a balloon designed for fluid is associated with premature deflation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/60,63\">",
"     60,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many practitioners still pack the anterior nose at this point because, without perfect apposition, some blood will pool anteriorly and exit the naris. Furthermore, some epistaxis episodes involve both anterior and posterior sources, especially in the setting of a coagulopathy or hereditary hemorrhagic telangiectasia. Be sure to maintain gentle traction on the Foley catheter while placing the anterior packing to avoid dislodgement of the former [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Be aware that petroleum-based products used for packing (such as BIPP or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ointment) can degrade the rubber of the balloon, possibly leading to rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Cotton packing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of balloon and Foley catheters, tamponade was achieved by means of cotton packing. This process involves feeding a small caliber red rubber hose through the nose and retrieving it from the oropharynx with a ring forceps (",
"    <a class=\"graphic graphic_figure graphicRef61765 \" href=\"UTD.htm?18/7/18548\">",
"     figure 2",
"    </a>",
"    ). A cotton pack is then tied to the oral end of the tube, with ties left long. The hose is then retracted through the nose, while digitally guiding the pack posteriorly, until it lodges against the posterior choana in the nasopharynx. The ties should now protrude through the nose. A second cotton pack or gauze roll is secured to the nasal end of the ties against the nares to anchor the pack. When such posterior cotton packing is placed, anterior packing is also generally needed.",
"   </p>",
"   <p>",
"    Although direct posterior packing has been superseded in many US settings, a recent small European trial, comparing this technique to a bicameral balloon device demonstrated that it remains an effective and safe alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This type of posterior packing usually necessitates hospitalization out of concern for hypoxic complications, as well as the risk of asphyxiation should the packing become dislodged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a suspected posterior source of bleeding require hospitalization in a bed with cardiac monitoring. Hospital admission may also be needed for patients with anterior packing who cannot be reasonably expected to return for prompt follow-up or who have serious comorbidities or concerning symptoms.",
"   </p>",
"   <p>",
"    Prolonged retention of nasal packing (greater than 72 hours) increases the risk of complications, including necrosis, toxic shock syndrome, sinus or nasolacrimal infections, and dislodgment. At 24 to 48 hours, the consultant is likely to remove any packing to inspect the site; further care may involve observation, repacking and observation, surgical intervention, or arterial embolization in an interventional radiology suite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective review of 250 patients hospitalized for epistaxis (including both anterior and posterior bleeds) found a 3 percent complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/11\">",
"     11",
"    </a>",
"    ]. Complications included synechiae (intranasal adhesions), aspiration, angina, myocardial infarction, and hypovolemia.",
"   </p>",
"   <p>",
"    The risks of posterior packing do NOT include the hypothetical \"nasopulmonary reflex,\" which was once believed to account for hypoventilation and decreased arterial oxygen tension in patients with posterior nasal packs, leading to recommendations for early surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/65\">",
"     65",
"    </a>",
"    ]. Studies have failed to identify physiologic changes attributable to posterior packing. As examples, one report of 10 healthy volunteers who underwent posterior nasal packing found no changes in pulmonary or cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/66\">",
"     66",
"    </a>",
"    ], and a prospective study of 19 hospitalized patients with posterior packing who were observed with continuous pulse oximetry for a total of 1200 patient-hours found only two episodes of transient desaturation, both of which were attributable to other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     TREATMENT FAILURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of conservative treatment failures varies according to available resources and the clinical scenario. Surgical treatment is often performed endoscopically and can include ligation of the sphenopalatine or anterior ethmoid artery (",
"    <a class=\"graphic graphic_figure graphicRef54180 \" href=\"UTD.htm?0/23/374\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/25,59,67\">",
"     25,59,67",
"    </a>",
"    ]. Angiographic embolization is increasingly common, with results that approximate those of surgical treatment (90 percent range) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. The rate of severe complications (eg, stroke, blindness) with embolization is approximately four percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have attempted to determine the likelihood of success and the relative costs of packing and observation, surgery, and embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/24,25,32,59,71\">",
"     24,25,32,59,71",
"    </a>",
"    ]. Interpretation of the results is made difficult by the small number of patients (ranging from 9 to 106), inability to perform blinded trials, and continual changes in surgical and nonsurgical management. As an example, past comparisons of medical and surgical management generally involve data obtained prior to the widespread use of endoscopic techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?1/41/1690/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the limited data, an otolaryngology consultant would likely make a recommendation for definitive treatment based upon individual patient factors, individual expertise, and available resources. Nasal packing and hospital admission for observation remains a viable alternative to the more technology-intensive approaches to intractable epistaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/50/1826?source=see_link\">",
"       \"Patient information: Nosebleeds (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/10/19617?source=see_link\">",
"       \"Patient information: Nosebleeds (epistaxis) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most epistaxis is anterior, occurring in Kiesselbach's plexus; posterior bleeds can cause significant hemorrhage. Anterior bleeds arise most commonly from trauma; other etiologies for anterior and posterior bleeds include coagulation or platelet disorders, vascular lesions, nasal tumors, and hereditary telangiectasias. Hypertension does not cause, but may prolong, epistaxis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      ordering coagulation studies routinely; they are indicated for anticoagulated patients. Obtain a complete blood count and a type and crossmatch for all patients with profuse bleeding. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Coagulation studies and other tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial measures for a patient with a nosebleed should include evaluating the airway and hemodynamic stability, and then having the patient perform basic tamponade maneuvers (",
"      <a class=\"graphic graphic_algorithm graphicRef82548 \" href=\"UTD.htm?29/15/29951\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial tamponade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nose should be examined with a nasal speculum. If an anterior bleeding source is seen, we suggest cautery with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"       silver nitrate",
"      </a>",
"      or electrocautery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Both sides of the septum should",
"      <strong>",
"       not",
"      </strong>",
"      be cauterized at the same time, to avoid septal necrosis. If no bleeding source is identified, the patient should be taught basic tamponade technique and instructed to return for recurrent bleeding. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Cautery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If bleeding continues despite cautery, nasal packing should be inserted into the anterior naris. Endoscopic cautery is an alternative, if available. We suggest the use of nasal tampons or nasal balloon catheters rather than gauze nasal packing (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The inserts are easier to apply and better tolerated than gauze packing, although the treatments appear equally effective in controlling bleeding. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Nasal packing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The appropriate use of antibiotic prophylaxis in patients with nasal packing remains controversial. We suggest that antibiotics not be given routinely for prophylaxis against infection in patients with anterior nasal packing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The decision to prescribe antibiotics is appropriately individualized to the patient. It may be reasonable to treat patients at greater risk of infection. Patients should be evaluated by an ENT specialist within 24 to 48 hours after packing is placed and should be warned about symptoms suggestive of toxic shock syndrome. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Antibiotics and toxic shock syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who continue to bleed after anterior packing most likely have a posterior bleed, and require posterior packing with a specially developed nasal balloon catheter or a Foley catheter. Petroleum-based products (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      ointment) may damage the balloon and should be avoided with posterior packing. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Treatment of posterior bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients who require posterior packing should be hospitalized for observation and assessment of the need for further intervention with surgery or angiographic embolization. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/1\">",
"      Kucik CJ, Clenney T. Management of epistaxis. Am Fam Physician 2005; 71:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/2\">",
"      Petruson B, Rudin R. The frequency of epistaxis in a male population sample. Rhinology 1975; 13:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/3\">",
"      Kotecha B, Fowler S, Harkness P, et al. Management of epistaxis: a national survey. Ann R Coll Surg Engl 1996; 78:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/4\">",
"      Tomkinson A, Roblin DG, Flanagan P, et al. Patterns of hospital attendance with epistaxis. Rhinology 1997; 35:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/5\">",
"      Daniell HW. Estrogen prevention of recurrent epistaxis. Arch Otolaryngol Head Neck Surg 1995; 121:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/6\">",
"      Nunez DA, McClymont LG, Evans RA. Epistaxis: a study of the relationship with weather. Clin Otolaryngol Allied Sci 1990; 15:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/7\">",
"      Okafor BC. Epistaxis: a clinical study of 540 cases. Ear Nose Throat J 1984; 63:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/8\">",
"      Juselius H. Epistaxis. A clinical study of 1,724 patients. J Laryngol Otol 1974; 88:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/9\">",
"      Lund VJ, Preziosi P, Hercberg S, et al. Yearly incidence of rhinitis, nasal bleeding, and other nasal symptoms in mature women. Rhinology 2006; 44:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/10\">",
"      Manfredini R, Gallerani M, Portaluppi F. Seasonal variation in the occurrence of epistaxis. Am J Med 2000; 108:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/11\">",
"      Pollice PA, Yoder MG. Epistaxis: a retrospective review of hospitalized patients. Otolaryngol Head Neck Surg 1997; 117:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/12\">",
"      Schlosser RJ. Clinical practice. Epistaxis. N Engl J Med 2009; 360:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/13\">",
"      Alvi A, Joyner-Triplett N. Acute epistaxis. How to spot the source and stop the flow. Postgrad Med 1996; 99:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/14\">",
"      Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol 1998; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/15\">",
"      Lavy J. Epistaxis in anticoagulated patients: educating an at-risk population. Br J Haematol 1996; 95:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/16\">",
"      Shah RK, Dhingra JK, Shapshay SM. Hereditary hemorrhagic telangiectasia: a review of 76 cases. Laryngoscope 2002; 112:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/17\">",
"      Fuchizaki U, Miyamori H, Kitagawa S, et al. Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Lancet 2003; 362:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/18\">",
"      Fiorella ML, Ross D, Henderson KJ, White RI Jr. Outcome of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia. Laryngoscope 2005; 115:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/19\">",
"      Liu JK, Gottfried ON, Amini A, Couldwell WT. Aneurysms of the petrous internal carotid artery: anatomy, origins, and treatment. Neurosurg Focus 2004; 17:E13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/20\">",
"      Chen D, Concus AP, Halbach VV, Cheung SW. Epistaxis originating from traumatic pseudoaneurysm of the internal carotid artery: diagnosis and endovascular therapy. Laryngoscope 1998; 108:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/21\">",
"      Hart RG, Pearce LA. In vivo antithrombotic effect of aspirin: dose versus nongastrointestinal bleeding. Stroke 1993; 24:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/22\">",
"      Beran M, Petruson B. Occurrence of epistaxis in habitual nose-bleeders and analysis of some etiological factors. ORL J Otorhinolaryngol Relat Spec 1986; 48:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/23\">",
"      Tay HL, Evans JM, McMahon AD, MacDonald TM. Aspirin, nonsteroidal anti-inflammatory drugs, and epistaxis. A regional record linkage case control study. Ann Otol Rhinol Laryngol 1998; 107:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/24\">",
"      Schaitkin B, Strauss M, Houck JR. Epistaxis: medical versus surgical therapy: a comparison of efficacy, complications, and economic considerations. Laryngoscope 1987; 97:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/25\">",
"      Pritikin JB, Caldarelli DD, Panje WR. Endoscopic ligation of the internal maxillary artery for treatment of intractable posterior epistaxis. Ann Otol Rhinol Laryngol 1998; 107:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/26\">",
"      Elden L, Montanera W, Terbrugge K, et al. Angiographic embolization for the treatment of epistaxis: a review of 108 cases. Otolaryngol Head Neck Surg 1994; 111:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/27\">",
"      Petruson B, Rudin R, Sv&auml;rdsudd K. Is high blood pressure an aetiological factor in epistaxis? ORL J Otorhinolaryngol Relat Spec 1977; 39:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/28\">",
"      Lubianca Neto JF, Fuchs FD, Facco SR, et al. Is epistaxis evidence of end-organ damage in patients with hypertension? Laryngoscope 1999; 109:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/29\">",
"      Lubianca-Neto JF, Bredemeier M, Carvalhal EF, et al. A study of the association between epistaxis and the severity of hypertension. Am J Rhinol 1998; 12:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/30\">",
"      Viehweg TL, Roberson JB, Hudson JW. Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg 2006; 64:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/31\">",
"      McGarry GW, Gatehouse S, Hinnie J. Relation between alcohol and nose bleeds. BMJ 1994; 309:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/32\">",
"      Druce HM, Spector SL, Fireman P, et al. Double-blind study of intranasal ipratropium bromide in nonallergic perennial rhinitis. Ann Allergy 1992; 69:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/33\">",
"      Keith P, Nieminen J, Hollingworth K, Dolovich J. Efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy 2000; 30:1460.",
"     </a>",
"    </li>",
"    <li>",
"     Riviello RJ. Otolaryngologic procedures. In: Clinical Procedures in Emergency Medicine, 4th, Roberts JR, Hedges JR.  (Eds), WB Saunders, Philadelphia 2004. p.1300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/35\">",
"      Thaha MA, Nilssen EL, Holland S, et al. Routine coagulation screening in the management of emergency admission for epistaxis--is it necessary? J Laryngol Otol 2000; 114:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/36\">",
"      Shakeel M, Trinidade A, Iddamalgoda T, et al. Routine clotting screen has no role in the management of epistaxis: reiterating the point. Eur Arch Otorhinolaryngol 2010; 267:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/37\">",
"      Krempl GA, Noorily AD. Use of oxymetazoline in the management of epistaxis. Ann Otol Rhinol Laryngol 1995; 104:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/38\">",
"      Loftus BC, Blitzer A, Cozine K. Epistaxis, medical history, and the nasopulmonary reflex: what is clinically relevant? Otolaryngol Head Neck Surg 1994; 110:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/39\">",
"      Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/40\">",
"      Katz RI, Hovagim AR, Finkelstein HS, et al. A comparison of cocaine, lidocaine with epinephrine, and oxymetazoline for prevention of epistaxis on nasotracheal intubation. J Clin Anesth 1990; 2:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/41\">",
"      Groudine SB, Hollinger I, Jones J, DeBouno BA. New York State guidelines on the topical use of phenylephrine in the operating room. The Phenylephrine Advisory Committee. Anesthesiology 2000; 92:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/42\">",
"      Middleton PM. Epistaxis. Emerg Med Australas 2004; 16:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/43\">",
"      Shehab Z, Pahor A. A valuable device in the management of epistaxis. J Laryngol Otol 1997; 111:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/44\">",
"      Toner JG, Walby AP. Comparison of electro and chemical cautery in the treatment of anterior epistaxis. J Laryngol Otol 1990; 104:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/45\">",
"      Breda SD, Jacobs JB, Lebowitz AS, Tierno PM Jr. Toxic shock syndrome in nasal surgery: a physiochemical and microbiologic evaluation of Merocel and NuGauze nasal packing. Laryngoscope 1987; 97:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/46\">",
"      Corbridge RJ, Djazaeri B, Hellier WP, Hadley J. A prospective randomized controlled trial comparing the use of merocel nasal tampons and BIPP in the control of acute epistaxis. Clin Otolaryngol Allied Sci 1995; 20:305.",
"     </a>",
"    </li>",
"    <li>",
"     Rapid Rhino Rev A Techguide. handbook.muh.ie/heent/ent/RR117%20gb%20Rev%20A%20Techguide%20Epistaxis.pdf (Accessed on April 7, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/48\">",
"      Badran K, Malik TH, Belloso A, Timms MS. Randomized controlled trial comparing Merocel and RapidRhino packing in the management of anterior epistaxis. Clin Otolaryngol 2005; 30:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/49\">",
"      Singer AJ, Blanda M, Cronin K, et al. Comparison of nasal tampons for the treatment of epistaxis in the emergency department: a randomized controlled trial. Ann Emerg Med 2005; 45:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/50\">",
"      Gudziol V, Mewes T, Mann WJ. Rapid Rhino: A new pneumatic nasal tamponade for posterior epistaxis. Otolaryngol Head Neck Surg 2005; 132:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/51\">",
"      Vaiman M, Segal S, Eviatar E. Fibrin glue treatment for epistaxis. Rhinology 2002; 40:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/52\">",
"      Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. Laryngoscope 2005; 115:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/53\">",
"      C&ocirc;t&eacute; D, Barber B, Diamond C, Wright E. FloSeal hemostatic matrix in persistent epistaxis: prospective clinical trial. J Otolaryngol Head Neck Surg 2010; 39:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/54\">",
"      McGlashan JA, Walsh R, Dauod A, et al. A comparative study of calcium sodium alginate (Kaltostat) and bismuth tribromophenate (Xeroform) packing in the management of epistaxis. J Laryngol Otol 1992; 106:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/55\">",
"      Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001; 161:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/56\">",
"      Pennekamp A, Tschirky P, Grossenbacher R. [Significance of Staphylococcus aureus in nose operations. Risk of toxic shock syndrome?]. HNO 1995; 43:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/57\">",
"      Jacobson JA, Stevens MH, Kasworm EM. Evaluation of single-dose cefazolin prophylaxis for toxic shock syndrome. Arch Otolaryngol Head Neck Surg 1988; 114:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/58\">",
"      Biswas D, Mal RK. Are systemic prophylactic antibiotics indicated with anterior nasal packing for spontaneous epistaxis? Acta Otolaryngol 2009; 129:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/59\">",
"      Rejas Ugena E, Trinidad Ruiz G, Alvarez Dom&iacute;nguez J, et al. [Utility of the surgical treatment for severe epistaxis by endoscopic approach of sphenopalatine and ethmoidal arteries]. Acta Otorrinolaringol Esp 2006; 57:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/60\">",
"      McFerran DJ, Edmonds SE. The use of balloon catheters in the treatment of epistaxis. J Laryngol Otol 1993; 107:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/61\">",
"      Goddard JC, Reiter ER. Inpatient management of epistaxis: outcomes and cost. Otolaryngol Head Neck Surg 2005; 132:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/62\">",
"      Burton MJ, Dor&eacute;e CJ. Interventions for recurrent idiopathic epistaxis (nosebleeds) in children. Cochrane Database Syst Rev 2004; :CD004461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/63\">",
"      Rashid M, Karagama Y. Inflation of Foley catheters for postnasal packing. J Laryngol Otol 2010; 124:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/64\">",
"      Garc&iacute;a Callejo FJ, Mu&ntilde;oz Fern&aacute;ndez N, Achiques Mart&iacute;nez MT, et al. [Nasal packing in posterior epistaxis. Comparison of two methods]. Acta Otorrinolaringol Esp 2010; 61:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/65\">",
"      Sessions RB. Nasal Hemorrhage. Otolaryngol Clin North Am 1973; 6:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/66\">",
"      Jacobs JR, Levine LA, Davis H, et al. Posterior packs and the nasopulmonary reflex. Laryngoscope 1981; 91:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/67\">",
"      Abdelkader M, Leong SC, White PS. Endoscopic control of the sphenopalatine artery for epistaxis: long-term results. J Laryngol Otol 2007; 121:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/68\">",
"      Tseng EY, Narducci CA, Willing SJ, Sillers MJ. Angiographic embolization for epistaxis: a review of 114 cases. Laryngoscope 1998; 108:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/69\">",
"      Moshaver A, Harris JR, Liu R, et al. Early operative intervention versus conventional treatment in epistaxis: randomized prospective trial. J Otolaryngol 2004; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/70\">",
"      Christensen NP, Smith DS, Barnwell SL, Wax MK. Arterial embolization in the management of posterior epistaxis. Otolaryngol Head Neck Surg 2005; 133:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/41/1690/abstract/71\">",
"      Monte ED, Belmont MJ, Wax MK. Management paradigms for posterior epistaxis: A comparison of costs and complications. Otolaryngol Head Neck Surg 1999; 121:103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 265 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1690=[""].join("\n");
var outline_f1_41_1690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anterior bleeds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Posterior bleeds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Coagulation studies and other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - General examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pretreatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Examination of the nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Distinguishing anterior and posterior bleeds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT OF ANTERIOR BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cautery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nasal packing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Nasal tampons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gauze packing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Nasal balloon catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Thrombogenic foams and gels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Persistent bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antibiotics and toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREATMENT OF POSTERIOR BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Balloon catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Foley catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Cotton packing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      TREATMENT FAILURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/265\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/265|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/15/29951\" title=\"algorithm 1\">",
"      Epistaxis management algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/265|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/23/374\" title=\"figure 1\">",
"      Anatomy medial nasal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/7/18548\" title=\"figure 2\">",
"      Nasal packing posterior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/265|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/47/33535\" title=\"picture 1\">",
"      Patient tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/5/39006\" title=\"picture 2\">",
"      Tampon and balloon packs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/265|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/3/41019\" title=\"table 1\">",
"      Epistaxis equipment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=related_link\">",
"      Evaluation of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=related_link\">",
"      Management of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/50/1826?source=related_link\">",
"      Patient information: Nosebleeds (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/10/19617?source=related_link\">",
"      Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_41_1691="Sodium terms PI";
var content_f1_41_1691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    What do labels about sodium mean?",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Sodium free",
"       </td>",
"       <td>",
"        A tiny amount of sodium in each serving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Very low sodium",
"       </td>",
"       <td>",
"        35 milligrams or less in each serving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Low sodium",
"       </td>",
"       <td>",
"        140 milligrams or less in each serving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Reduced sodium",
"       </td>",
"       <td>",
"        Usual level of sodium is reduced by 25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Light or lite in sodium",
"       </td>",
"       <td>",
"        Usual level of sodium is reduced by 50 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1691=[""].join("\n");
var outline_f1_41_1691=null;
var title_f1_41_1692="Presumptive eligibility SSI";
var content_f1_41_1692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Presumptive eligibility for supplemental security income in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Amputation of two limbs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amputation of a leg at the hip",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes with amputation of a foot",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cerebral palsy, muscular dystrophy, or muscular atrophy and marked difficulty in walking, speaking, or coordinating the hands",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Total blindness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Total deafness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Down syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bed confinement or immobility because of a longstanding condition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe mental deficiency in a child older than 7 years of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stroke or cerebral vascular accident that occurred more than 3 months ago, with continued marked difficulty in walking or using a hand or arm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Symptomatic human immunodeficiency virus infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birth weight less than 1200 g in a child younger than 12 months of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birth weight between 1200 and 2000 g combined with specific gestational ages",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Terminal cancer with a life expectancy of 6 months or less or in hospice care (physician confirmation required)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inability to ambulate without a walker or equivalent device 2 weeks after a spinal cord injury",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SSI: supplemental security income.",
"     <br>",
"      * Children with these conditions can receive SSI benefits for up to six months while formal eligibility is being determined. Pediatric health care providers should provide parents with a statement about the diagnosis and severity of the child's condition.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: American Academy of Pediatrics: Policy statements--Supplemental Security Income (SSI) for children and youth with disabilities. Pediatrics 2009; 124:1702.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1692=[""].join("\n");
var outline_f1_41_1692=null;
var title_f1_41_1693="Sex cord stromal tumors";
var content_f1_41_1693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO histologic classification of ovarian tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       1. Surface epithelial-stromal tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1.1 Serous tumors: benign, borderline, malignant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1.2 Mucinous tumors, endocervical-like and intestinal-type: benign, borderline, malignant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1.3 Endometrioid tumors: benign, borderline, malignant, epithelial-stromal and stromal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1.4 Clear cell tumors: benign, borderline, malignant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1.5 Transitional cell tumors: Brenner tumor, Brenner tumor of borderline malignancy, malignant Brenner tumor, transitional cell carcinoma (non-Brenner type)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1.6 Squamous cell tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1.7 Mixed epithelial tumors (specify components): benign, borderline, malignant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1.8 Undifferentiated carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       2. Sex cord-stromal tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2.1 Granulosa-stromal cell tumors: granulosa cell tumors, thecoma-fibroma group",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2.2 Sertoli-stromal cell tumors, androblastomas: well-differentiated, Sertoli-Leydig cell tumor of intermediate differentiation, Sertoli-Leydig cell tumor poorly differentiated (sarcomatoid), retiform",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2.3 Sex cord tumor with annular tubules",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2.4 Gynandroblastoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2.5 Unclassified",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2.6 Steroid (lipid) cell tumors: stromal luteoma, Leydig cell tumor, unclassified",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       3. Germ cell tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3.1 Dysgerminoma: variant - with syncytiotrophoblast cells",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3.2 Yolk sac tumors (endodermal sinus tumors): polyvesicular vitelline tumor, hepatoid, glandular",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3.3 Embryonal carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3.4 Polyembryoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3.5 Choriocarcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3.6 Teratomas: immature, mature, monodermal, mixed germ cell",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Gonadoblastoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Germ cell sex cord-stromal tumor of nongonadoblastoma type",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Tumors of rete ovarii",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Mesothelial tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Tumors of uncertain origin and miscellaneous tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. Gestational trophoblastic diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10. Soft tissue tumors not specific to ovary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11. Malignant lymphomas, leukemias, and plasmacytomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12. Unclassified tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13. Secondary (metastatic) tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       14. Tumorlike lesions",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Scully R, Sobin L. Histological typing of ovarian tumours, volume 9. New York: Springer Berlin 1999. Copyright &copy; 1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1693=[""].join("\n");
var outline_f1_41_1693=null;
var title_f1_41_1694="Contents: Urticaria and angioedema";
var content_f1_41_1694=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Urticaria and angioedema",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Urticaria and angioedema",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Angioedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/37/37465\">",
"           ACE inhibitor-induced angioedema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26824\">",
"           Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/20/25927\">",
"           Acquired C1 inhibitor deficiency: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15641\">",
"           An overview of angioedema: Clinical features, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/52/19272\">",
"           Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33864\">",
"           Hereditary angioedema: Pathogenesis and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29658\">",
"           Hereditary angioedema: Prevention of attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33657\">",
"           Hereditary angioedema: Treatment of acute attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/61/5080\">",
"           Type III hereditary angioedema",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urticaria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30010\">",
"           Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/7/117\">",
"           Chronic urticaria: Standard management and patient education",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/53/30554\">",
"           Chronic urticaria: Treatment of refractory symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/22/15721\">",
"           Cold urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24666\">",
"           Physical urticarias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-1B2D13CE77-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f1_41_1694=[""].join("\n");
var outline_f1_41_1694=null;
var title_f1_41_1695="Incidence of DSPN";
var content_f1_41_1695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Incidence of peripheral neuropathy and rate of HAART use among 7362 patients in the HIV outpatient study (HOPS) cohort",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lichtenstein, KA, Armon, C, Baron, A, et al. Modification of the incidence of drug-associated symmetrical periheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40:148. Copyright &copy; 2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_41_1695=[""].join("\n");
var outline_f1_41_1695=null;
